Browse by Poster Presenter

Tweets by ASCPT 2023 Annual Meeting

Browse by Poster Presenter

Type here to filter the list

A
Abutarif, Malaz

Daiichi Sankyo
PI-016 - EFFECT OF MILD AND MODERATE HEPATIC IMPAIRMENT ON QUIZARTINIB PHARMACOKINETICS.
Malaz Abutarif
Favorite
Ahmed, Nusrat

University of Nebraska Medical Center
PII-121 - CONTRIBUTION OF INFLAMMATION AND OBESITY TO VARIABILITY IN MIDAZOLAM PHARMACOKINETICS IN CHILDREN.
Nusrat Ahmed
Favorite
Ajavon-Hartmann, Toni

Bristol Myers Squibb
PII-063 - MODELING AND SIMULATION TO SUPPORT APIXABAN DOSE RECOMMENDATION FOR THROMBOEMBOLISM PREVENTION IN PEDIATRIC SUBJECTS WITH CONGENITAL OR ACQUIRED HEART DISEASE REQUIRING ANTICOAGULATION – SAXOPHONE STUDY.
Toni Ajavon-Hartmann
Favorite
Aldhafiri, Wafaa

University of Nebraska Medical Center
PT-024 - PHARMACOKINETICS AND TISSUE DISTRIBUTION OF A LIPID-BASED EXTENDED-RELEASE NANO-FORMULATION OF MO-OH-NAP TROPOLONE TO ENHANCE PULMONARY DELIVERY.
Wafaa Aldhafiri
Favorite
Alghamdi, Alaa

Cincinnati Children's Hospital Medical Center
PT-009 - ASSOCIATION BETWEEN TACROLIMUS AND CYP3A5 GENOTYPE IN PEDIATRIC KIDNEY TRANSPLANT.
Alaa Alghamdi
Favorite
Alkhafaji, Silver

University of California, San Francisco
PII-081 - POPULATION PHARMACOKINETICS (PK) OF ETHAMBUTOL IN TUBERCULOSIS PATIENTS – TUBERCULOSIS TRIALS CONSORTIUM (TBTC) STUDY A5349/S31.
Silver Alkhafaji
Favorite
Almoslem, Mohammed

University of Florida
PII-072 - PHARMACOKINETICS AND PHARMACODYNAMICS MODELING OF ACETAMINOPHEN AND IBUPROFEN TO EVALUATE THE TIME TO PATENT DUCTUS ARTERIOSUS CLOSURE IN PRETERM NEONATES.
Mohammed Almoslem
Favorite
Alrajeh, Khalifa

Virginia Commonwealth University
PI-032 - THE FREQUENCY OF SLCO1B1*5 IN WOMEN OF ASIAN, NATIVE HAWAIIAN, AND PACIFIC ISLANDERS SUBGROUPS: STEPS TO INCREASE RACIAL DIVERSITY IN PHARMACOGENETIC RESEARCH.
Khalifa Alrajeh
Favorite
PWIV-005 - THE FREQUENCY OF SLCO1B1*5 IN WOMEN OF ASIAN, NATIVE HAWAIIAN, AND PACIFIC ISLANDERS SUBGROUPS: STEPS TO INCREASE RACIAL DIVERSITY IN PHARMACOGENETIC RESEARCH.
Khalifa Alrajeh
Favorite
Amore, Benny

Esperion Therapeutics, Inc.
PI-057 - DOSE–RESPONSE MODEL PREDICTIONS OF THE PHARMACODYNAMIC EFFECT OF BEMPEDOIC ACID, A COMPETITIVE INHIBITOR OF ATP CITRATE LYASE, IN COMBINATION WITH EZETIMIBE AND STATINS.
Benny Amore
Favorite
Anderson, Kacey

EQRx International, Inc.
PII-113 - PHARMACOKINETICS OF AUMOLERTINIB IN HEALTHY CHINESE SUBJECTS AND NON-CHINESE SUBJECTS.
Kacey Anderson
Favorite
Arslan, Meliksah

Marmara University School of Medicine
PII-032 - SUBSTANCE USE DISORDERS: GLUCOCORTICOID SIGNALING REGULATES THE EXPRESSION OF PTPRD IN HUMAN CNS CELLS.
Meliksah Arslan
Favorite
Asao, Tetsuhiko

Juntendo University Hospital
PII-038 - MULTICENTER PHARMACOKINETIC STUDY OF PEMBROLIZUMAB FOR NON-SMALL CELL LUNG CANCER IN OLDER ADULTS AGED OVER 75 YEARS.
Tetsuhiko Asao
Favorite
Asthana-Nijjar, Rashi

University of Toronto
PT-003 - EXPRESSION OF ABCB1 IS DECREASED IN PLACENTA OF WOMEN WITH AUTOIMMUNE DISEASE AND IN CYTOKINE- TREATED PLACENTAL EXPLANTS.
Rashi Asthana-Nijjar
Favorite
Avachat, Charul

University of Minnesota
PI-083 - CHARACTERIZATION OF THE US FOOD AND DRUG ADMINISTRATION POST-MARKETING COMMITMENTS AND REQUIREMENTS FOR PREGNANCY AND LACTATION.
Charul Avachat
Favorite
B
Bae, Sungyeun

Seoul National University
PI-026 - EFFECT OF CYP2D6 PHENOTYPE ON PHARMACOKINETICS OF DWN12088, A NOVEL PROLYL-TRNA SYNTHETASE INHIBITOR, IN A FIRST-IN HUMAN STUDY.
Sungyeun Bae
Favorite
Balazki, Pavel

esqLABS GmbH
PII-094 - 4Β-OH CHOLESTEROL AS ENDOGENOUS BIOMARKER FOR CYP3A4 INDUCER DDI STUDIES – A PBPK PLATFORM FOR IN SILICO COMPOUND TESTING.
Pavel Balazki
Favorite
PWI-002 - 4Β-OH CHOLESTEROL AS ENDOGENOUS BIOMARKER FOR CYP3A4 INDUCER DDI STUDIES – A PBPK PLATFORM FOR IN SILICO COMPOUND TESTING.
Pavel Balazki
Favorite
Bank, Paul

University of Amsterdam
EP-015 - EXPLAINING INTERPATIENT VARIABILITY OF ADALIMUMAB RESPONSE IN CHRONIC PLAQUE PSORIASIS BY PHARMACOKINETIC-PHARMACODYNAMIC MODELLING: RESULTS FROM THE OPTIMAP STUDY.
Paul Bank
Favorite
Berger, Benjamin

Idorsia Pharmaceuticals Ltd
PI-062 - EFFECT OF ACT-539313, A SELECTIVE OREXIN-1 RECEPTOR ANTAGONIST, ON THE CYTOCHROME P450 2C9, 2C19, AND 3A4 SUBSTRATES FLURBIPROFEN, OMEPRAZOLE, AND MIDAZOLAM USING A COCKTAIL APPROACH.
Benjamin Berger
Favorite
PII-054 - EFFECT OF COMPLEMENT FACTOR 5A RECEPTOR 1 (C5AR1) ANTAGONIST ACT-1014-6470 ON THE CYTOCHROME P450 2C19 AND 3A4 SUBSTRATES OMEPRAZOLE AND MIDAZOLAM IN A COCKTAIL STUDY IN HEALTHY SUBJECTS.
Benjamin Berger
Favorite
Bhagwat, Sharvari

Inhibrx
PII-092 - YOU MUST CHOOSE, BUT CHOOSE WISELY – PHASE 2 DOSE SELECTION FOR INBRX-109, A TETRAVALENT DEATH RECEPTOR 5 (DR5) AGONIST ANTIBODY.
Sharvari Bhagwat
Favorite
Bhatnagar, Sumit

Abbvie Inc.
PII-004 - PHASE 1 DEVELOPMENT OF RAVAGALIMAB, AN ANTI CD40 MONOCLONAL ANTIBODY, TO SUPPORT DOSE SELECTION FOR PHASE 2.
Sumit Bhatnagar
Favorite
Bird, Helen

Johns Hopkins University
PII-128 - HOW DOES CLEARANCE OF ILLICITLY MANUFACTURED FENTANYL AFFECT WITHDRAWAL DURING EARLY BUPRENORPHINE TREATMENT?
Helen Bird
Favorite
Block, Michael

Bayer AG
PI-093 - A COMPREHENSIVE MIDD APPROACH TO ASSESS THE SAFETY AND EFFICACY OF TARGETED-THORIUM-CONJUGATES IN PATIENTS FOR EARLY DECISION MAKING.
Michael Block
Favorite
PII-123 - A MODEL-BASED META-ANALYSIS TO ASSESS THE SIMILARITIES AND DIFFERENCES OF CLINICAL SAFETY OF TARGETED-THORIUM-CONJUGATES IN PATIENTS.
Michael Block
Favorite
Boof, Marie-Laure

Idorsia Pharmaceuticals Ltd
PI-034 - A MULTI-PURPOSE FIRST-IN-HUMAN STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ACT-777991, AN ORAL C-X-C MOTIF CHEMOKINE RECEPTOR 3 (CXCR3) ANTAGONIST.
Marie-Laure Boof
Favorite
Brees, Laurane

Janssen Pharmaceuticals
PII-012 - FROM RIFAMPIN TO CARBAMAZEPINE: HOW TO PROPERLY MANAGE SAFETY IN A CHANGING DRUG-DRUG-INTERACTION TRIAL LANDSCAPE.
Laurane Brees
Favorite
Brooks, Jordan

University of California, San Francisco
PI-052 - CYCLOPHOSPHAMIDE POPULATION PHARMACOKINETICS IN PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION.
Jordan Brooks
Favorite
Brown, Karen

University of Montana
PI-089 - NATIONAL MEETING ON COMMUNITY ENGAGED RESEARCH TOWARDS PRECISION MEDICINE WITH AMERICAN INDIAN AND ALASKA NATIVE PEOPLE.
Karen Brown
Favorite
C
Caratzas, Eleni

University of North Carolina at Chapel Hill Janssen: Pharmaceutical Companies of Johnson & Johnson
EP-036 - ESTIMATING TARGET ENGAGEMENT USING SINGLE POST-DOSE TIMEPOINT TO SUPPORT FURTHER CLINICAL DEVELOPMENT.
Eleni Caratzas
Favorite
Cardona, Panli

Amgen Inc.
EP-005 - AN OPEN-LABEL BIOEQUIVALENCE STUDY IN HEALTHY VOLUNTEERS TO COMPARE THE PHARMACOKINETICS OF TWO DIFFERENT TABLET STRENGTHS OF SOTORASIB.
Panli Cardona
Favorite
EP-006 - AN OPEN-LABEL STUDY TO ASSESS THE EFFECT OF COADMINISTRATION OF SOTORASIB ON THE PHARMACOKINETICS OF ROSUVASTATIN, A BREAST CANCER RESISTANCE PROTEIN SUBSTRATE, IN HEALTHY SUBJECTS.
Panli Cardona
Favorite
Carrasquilla, Santiago

US Food and Drug Administration
PI-020 - IMPACT OF TYROSINE KINASE INHIBITOR (TKI) DOSAGE MODIFICATIONS ON PROGRESSION-FREE SURVIVAL (PFS) IN THE TREATMENT OF EGFR-MUTATED NON-SMALL CELL LUNG CANCER (NSCLC).
Santiago Carrasquilla
Favorite
Cascorbi, Ingolf

University of Kiel
E-002 - FURTHER EVIDENCE ON ABCB1 DRUG TRANSPORTER IN THE RESPONSE TO TEMOZOLOMIDE, CARMUSTINE AND LOMUSTINE IN GLIOBLASTOMA MULTIFORME.
Ingolf Cascorbi
Favorite
Chang, Hsuan Ping

University at Buffalo
LB-008 - DEVELOPMENT OF HOLISTIC EXPOSURE-TOXICITY RELATIONSHIPS FOR MMAE-BASED ADCS: A GENERALIZED PK/PD MODEL.
Hsuan Ping Chang
Favorite
Chang, Vincent

Gilead Sciences
PII-020 - A MATHEMATICAL MODEL FOR SELECTING REGIMEN COMPOSITION AND DURATION BASED ON PHENOTYPE FOR PATIENTS WITH DRUG-SUSCEPTIBLE TUBERCULOSIS.
Vincent Chang
Favorite
PII-065 - OPTIMAL DOSING OF RIFAPENTINE IN NOVEL 4-MONTH HIGH-DOSE RIFAPENTINE WITH MOXIFLOXACIN REGIMEN FOR THE TREATMENT OF DRUG-SUSCEPTIBLE TUBERCULOSIS.
Vincent Chang
Favorite
PWII-002 - A MATHEMATICAL MODEL FOR SELECTING REGIMEN COMPOSITION AND DURATION BASED ON PHENOTYPE FOR PATIENTS WITH DRUG-SUSCEPTIBLE TUBERCULOSIS.
Vincent Chang
Favorite
Chan, Sze Wa

Caritas Institute of Higher Education
EP-007 - CENTRAL ADMINISTRATION OF COCAINE- AND AMPHETAMINE-REGULATED TRANSCRIPT PEPTIDE REDUCES CISPLATIN-INDUCED EMESIS AND C-FOS EXPRESSION IN SUNCUS MURINUS.
Sze Wa Chan
Favorite
Chekka, Lakshmi Manasa

Koniag Government Services
EP-028 - EVALUATING THE UTILITY OF PROTEOMICS FOR THE IDENTIFICATION OF CIRCULATING PHARMACODYNAMIC BIOMARKERS OF IFNΒ-1A BIOLOGICS.
Lakshmi Manasa Chekka
Favorite
Chen, Buyun

Gilead Sciences
PII-096 - MODEL INFORMED DRUG INTERACTION STUDY DESIGN FOR VESATOLIMOD AND CYP3A/P-GP MODULATORS USING PBPK.
Buyun Chen
Favorite
Chen, Ying

Pfizer
PI-043 - CHARACTERIZATION OF GEMTUZUMAB OZOGAMICIN PHARMACOKINETICS IN ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA FOLLOWING FRACTIONATED DOSING REGIMEN.
Ying Chen
Favorite
PII-053 - CONCENTRATION-QT MODELING ANALYSIS OF GEMTUZUMAB OZOGAMICIN FOLLOWING FRACTIONATED DOSING REGIMEN IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA.
Ying Chen
Favorite
Cheruvu, Hanumanth

Parexel International
EP-021 - PBPK MODELING OF A NARROW THERAPEUTIC INDEX DRUG AND APPLICATION IN PREDICTING DOSE ESCALATION SCENARIOS, FOOD EFFECT, DDI AND SPECIAL POPULATION.
Hanumanth Cheruvu
Favorite
Cheung, Kathy

Genentech
PI-092 - RECENT TRENDS IN PEDIATRIC DOSING STRATEGY FROM 2000-2019: A NATURAL LANGUAGE PROCESSING/DRUG LABEL ANALYSIS.
Kathy Cheung
Favorite
PWIV-002 - RECENT TRENDS IN PEDIATRIC DOSING STRATEGY FROM 2000-2019: A NATURAL LANGUAGE PROCESSING/DRUG LABEL ANALYSIS.
Kathy Cheung
Favorite
Chevalier, Rachel

Children's Mercy Kansas City
PI-042 - BUDESONIDE EMBEDDED ALGINATE THIN FILMS SHOW TUNABLE SUSTAINED RELEASE.
Rachel Chevalier
Favorite
Chicoine, Noah

Northeastern University
PI-053 - DEVELOPING A MECHANISTIC MODEL OF IL-15 MEDIATED NK CELL PROLIFERATION WITH IMPLICATIONS IN IMPROVING CAR NK CELL THERAPY EFFICACY.
Noah Chicoine
Favorite
Chowdhury, S M Atiqur

Takeda Development Center Americas Inc.
PI-012 - CLINICAL EFFICACY OF CAR-T AND CAR-NK FOR THE TREATMENT OF HEMATOLOGIC AND SOLID TUMOR MALIGNANCIES: A SYSTEMATIC REVIEW AND META-ANALYSIS.
S M Atiqur Chowdhury
Favorite
Chung, Woo Kyung

Seoul National University Hospital
PII-011 - DRUG-DRUG INTERACTION BETWEEN THE NOVEL SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR, DWP16001, WITH GEMIGLIPTIN AND METFORMIN IN HEALTHY SUBJECTS.
Woo Kyung Chung
Favorite
Cleary, Yumi

F.Hoffmann-La Roche Ltd.
EP-035 - MECHANISTIC POPULATION PHARMACOKINETIC MODELLING OF RISDIPLAM FOR EXTRAPOLATION OF EXPOSURE AND CYP3A DRUG-DRUG INTERACTION IN NEONATES WITH SPINAL MUSCULAR ATROPHY.
Yumi Cleary
Favorite
Collins, Joseph

University of Florida
PT-025 - A NOVEL REGULATORY VARIANT PROMOTES CYP2D6 ALTERNATIVE SPLICING AND REDUCES FULL-LENGTH CYP2D6 PROTEIN LEVELS IN LIVER SAMPLES.
Joseph Collins
Favorite
Collins, Kimberly

Critical Path Institute
LB-002 - RESIDUAL C-PEPTIDE IS ASSOCIATED WITH LOWER HYPOGLYCEMIA RISK IN NEW-ONSET TYPE 1 DIABETES – A POOLED ANALYSIS OF 2780 ADULTS AND CHILDREN.
Kimberly Collins
Favorite
Corriere, Meghan

Vanderbilt University
PT-013 - CONCURRENT GABAPENTIN AND OPIOID USE AND RISK OF MORTALITY IN MEDICARE RECIPIENTS WITH NON-CANCER PAIN.
Meghan Corriere
Favorite
RWE-002 - CONCURRENT GABAPENTIN AND OPIOID USE AND RISK OF MORTALITY IN MEDICARE RECIPIENTS WITH NON-CANCER PAIN.
Meghan Corriere
Favorite
D
Dao, Justine

Galapagos SASU
PI-064 - EFFECTS OF GLPG3970 ON SULFASALAZINE AND METHOTREXATE PHARMACOKINETICS IN HEALTHY ADULTS: RESULTS OF TWO OPEN-LABEL, PHASE I, DRUG–DRUG INTERACTION STUDIES.
Justine Dao
Favorite
Darwish, Mona

Acadia Pharmaceuticals Inc.
EP-023 - POPULATION PHARMACOKINETIC MODELLING TO CONFIRM WEIGHT-BASED BANDED DOSING AND EXPOSURE-RESPONSE EFFICACY ANALYSES TO SUPPORT TROFINETIDE TREATMENT IN RETT SYNDROME.
Mona Darwish
Favorite
EP-024 - POPULATION PHARMACOKINETIC MODELLING TO PREDICT TROFINETIDE EXPOSURE AND EXPOSURE-RESPONSE SAFETY ANALYSES IN GIRLS WITH RETT SYNDROME AGED 2–4 YEARS.
Mona Darwish
Favorite
Datta-Mannan, Amita

Eli Lilly and Company
EP-029 - IDENTIFICATION OF A SAFE AND TOLERABLE CARBAMAZEPINE DOSING PARADIGM THAT FACILITATES EFFECTIVE CYP3A INDUCTION EVALUATION.
Amita Datta-Mannan
Favorite
Dauki, Anees

Gilead Sciences
PII-083 - POPULATION PHARMACOKINETICS OF GS-3583 IN HEALTHY VOLUNTEERS AND PATIENTS WITH ADVANCED SOLID TUMORS.
Anees Dauki
Favorite
Davies, Rupert

Alpine Immune Sciences
PI-059 - EARLY CLINICAL PK/PD MODELING AND SIMULATION OF ALPN-303, A POTENT DUAL BAFF/APRIL ANTAGONIST, TO SUPPORT FIRST-IN-DISEASE CLINICAL TRIALS IN SYSTEMIC LUPUS ERYTHEMATOSUS AND OTHER B CELL-RELATED DISEASES.
Rupert Davies
Favorite
Day, Jeanine

University at Buffalo
PT-008 - INFLUENCE OF MCT6 ON PLATINUM DISPOSITION AND OTOTOXICITY.
Jeanine Day
Favorite
de Hoop-Sommen, Marika

Radboud University Medical Center
PII-103 - REGISTERED DIGOXIN DOSES FOR CHILDREN DO NOT LEAD TO OPTIMAL EXPOSURE: A PBPK STUDY.
Marika de Hoop-Sommen
Favorite
Diao, Lei

Fosun Pharma
PI-105 - POPULATION PHARMACOKINETICS OF FS-1502, AN HER2 ANTIBODY-DRUG CONJUGATE (ADC), IN PATIENTS WITH HER2 EXPRESSED ADVANCED MALIGNANT SOLID TUMORS.
Lei Diao
Favorite
Dogterom, Peter

QPS Netherlands
PII-007 - EXPERIENCES OF CEREBROSPINAL FLUID COLLECTION, EITHER BY SERIAL SAMPLING OR BY LUMBER PUNCTURES, IN CLINICAL PHARMACOLOGY RESEARCH.
Peter Dogterom
Favorite
Dong, Min

Cincinnati Children's Hospital Medical Center
PI-087 - DEVELOPMENTAL CHANGES OF HYDROXYUREA PHARMACOKINETICS IN CHILDREN WITH SICKLE CELL ANEMIA.
Min Dong
Favorite
PWIV-003 - DEVELOPMENTAL CHANGES OF HYDROXYUREA PHARMACOKINETICS IN CHILDREN WITH SICKLE CELL ANEMIA.
Min Dong
Favorite
Drabison, Thomas

The Ohio State University
PI-019 - IDENTIFICATION OF S100A9 AS A THERAPEUTIC TARGET IN PACLITAXEL-INDUCED PERIPHERIAL NEUROPATHY (PIPN).
Thomas Drabison
Favorite
Dunbar, Joi

Sage Therapeutics, Inc.
PI-072 - IN VITRO AND IN VIVO POTENTIAL OF ZURANOLONE TO CAUSE CYP-MEDIATED DRUG-DRUG INTERACTIONS.
Joi Dunbar
Favorite
PII-089 - THE EFFECTS OF CYP3A INDUCTION AND INHIBITION ON ZURANOLONE PHARMACOKINETICS IN HEALTHY ADULTS.
Joi Dunbar
Favorite
Dunvald, Ann-Cathrine

University of Southern Denmark
PT-027 - DO GLUCOSE-LOWERING DRUGS AFFECT DRUG METABOLISM AND WARFARIN EFFICACY?
Ann-Cathrine Dunvald
Favorite
Duong, Quoc-Viet

US Food and Drug Administration
PI-078 - LEVERAGING A DERMAL PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL OF A TOPICAL CREAM TO EXPLORE THE BIOEQUIVALENCE SAFE SPACE FOR INFLUENTIAL FORMULATION ATTRIBUTES.
Quoc-Viet Duong
Favorite
E
Edwina, Angela Elma

Katholieke Universiteit Leuven
PI-046 - COMPARISON OF A COLORIMETRIC ASSAY AND ULTRA-PERFORMANCE LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY FOR QUANTIFYING PARACETAMOL PLASMA CONCENTRATIONS: DESIGN OF A GERIATRIC PHARMACOKINETICS STUDY.
Angela Elma Edwina
Favorite
El Rouby, Nihal

University of Cincinnati
PI-031 - PILOT, FEASIBILITY TESTING OF DPYD AND UGT1A1 PRIOR TO CHEMOTHERAPY IN A COMMUNITY-BASED CANCER CENTER.
Nihal El Rouby
Favorite
PII-046 - GENOME WIDE ASSOCIATION STUDY (GWAS) OF SECOND-GENERATION ANTIPSYCHOTICS (SGA)-INDUCED METABOLIC SYNDROME (METS) IN BIOME BIOBANK.
Nihal El Rouby
Favorite
PWIII-001 - PILOT, FEASIBILITY TESTING OF DPYD AND UGT1A1 PRIOR TO CHEMOTHERAPY IN A COMMUNITY-BASED CANCER CENTER.
Nihal El Rouby
Favorite
El-Zailik, Asma

Vir Biotechnology
LB-009 - IMPACT OF INTRAMUSCULAR INJECTION SITE ON SOTROVIMAB PHARMACOKINETICS.
Asma El-Zailik
Favorite
Emery, Maurice

Esperion Therapeutics, Inc.
PI-044 - CLINICAL DRUG–DRUG INTERACTION STUDIES TO EVALUATE THE EFFECTS OF BEMPEDOIC ACID, A SMALL-MOLECULE INHIBITOR OF ATP CITRATE LYASE, ON THE PHARMACOKINETICS OF CONCOMITANT STATIN THERAPIES.
Maurice Emery
Favorite
Enogieru, Osatohanmwen

Amgen
EP-030 - PRECLINICAL IN-VITRO ASSAYS EVALUATING PROTEIN DEGRADERS (PDS) ASSOCIATE WITH ORAL BIOAVAILABILITY AND VOLUME OF DISTRIBUTION IN TISSUES.
Osatohanmwen Enogieru
Favorite
F
Fashe, Muluneh

University of North Carolina at Chapel Hill
PI-088 - IMPACT OF PREGNANCY ON THE PHARMACOKINETICS AND METABOLISM OF NICOTINAMIDE IN HUMANS.
Muluneh Fashe
Favorite
PWIV-004 - IMPACT OF PREGNANCY ON THE PHARMACOKINETICS AND METABOLISM OF NICOTINAMIDE IN HUMANS.
Muluneh Fashe
Favorite
Felderman, Jacob

University of California, San Diego
PII-001 - COMPARISON OF THE IMMUNOGENICITY RISK OF BIOTHERAPEUTICS ADMINISTERED VIA INTRAVENOUS VS. SUBCUTANEOUS ROUTE OF ADMINISTRATION.
Jacob Felderman
Favorite
Fitch, Rick

Xeris Pharmaceuticals
LB-003 - A PHASE I, RANDOMIZED, OPEN-LABEL, CROSSOVER, FIXED-SEQUENCE STUDY TO EVALUATE THE PK, D0SE-PROPORTIONALITY, BIOAVAILABILITY, AND TOLERABILITY OF SUBCUTANEOUS LEVOTHYROXINE SODIUM (XP-8121) IN HEALTHY ADULT SUBJECTS.
Rick Fitch
Favorite
Flori, Lorenzo

University of California, San Francisco
EP-016 - GATIFLOXACIN EXPOSURE IN THE LESION AS TARGET SITE OF GATIFLOXACIN IN A RABBIT MODEL OF TUBERCULOSIS: COMPARISON WITH THE OUTCOMES FROM THE PHASE III OFLOTUB TRIAL.
Lorenzo Flori
Favorite
Fochesato, Anna

University of California, San Francisco
PT-006 - A LESION-CENTRIC AND TARGET-SPECIFIC PKPD MODEL OF PYRAZINOIC ACID IN PATIENTS WITH TUBERCULOSIS.
Anna Fochesato
Favorite
Freriksen, Jolien

Radboud University Medical Center
LB-012 - ETHANOL AS AN EXCIPIENT IN DRUG FORMULATIONS ADMINISTERED TO NEONATES: PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO INFORM SAFETY.
Jolien Freriksen
Favorite
Fukushima, Keizo

Kobe Gakuin University
LB-010 - PEDIATRIC POPULATION PHARMACOKINETIC MODEL DEVELOPMENT FOR ORAL AMOXICILLIN AND CLAVULANIC: LEVERAGING LITERATURE DATA FOR MODEL-INFORMED DRUG EXPOSURE ANALYSIS IN YOUNG CHILDREN.
Keizo Fukushima
Favorite
G
Gahir, Sarabjit

Bellus Health Inc
PII-013 - IN VITRO, IN SILICO, AND CLINICAL INVESTIGATIONS OF BLU-5937 AS PERPETRATOR OF DRUG-DRUG INTERACTIONS.
Sarabjit Gahir
Favorite
Gaiazov, Sabrina

Indivior
E-003 - ASSESSMENT OF TREATMENT PATHS FOR OUD PATIENTS AFTER AN ACUTE OUD EVENT.
Sabrina Gaiazov
Favorite
Gelineau-Morel, Rose

Children's Mercy Kansas City
PII-105 - INVESTIGATION OF THE BIOTRANSFORMATION OF TRIHEXYPHENIDYL AND APPLICATION TO DYSTONIC CEREBRAL PALSY.
Rose Gelineau-Morel
Favorite
Gerhart, Jacqueline

Pfizer
PI-005 - USING REAL WORLD EVIDENCE (RWE) TO ASSESS DRUG-DRUG INTERACTION (DDI) BETWEEN PAXLOVID AND THE TOP 100 PRESCRIBED DRUGS IN THE US.
Jacqueline Gerhart
Favorite
RWE-001 - USING REAL WORLD EVIDENCE (RWE) TO ASSESS DRUG-DRUG INTERACTION (DDI) BETWEEN PAXLOVID AND THE TOP 100 PRESCRIBED DRUGS IN THE US.
Jacqueline Gerhart
Favorite
Gershuny, Victoria

US Food and Drug Administration
E-001 - EFFECT OF PAROXETINE OR QUETIAPINE COMBINED WITH OXYCODONE VS OXYCODONE ALONE ON VENTILATION DURING HYPERCAPNIA: A RANDOMIZED CLINICAL TRIAL.
Victoria Gershuny
Favorite
Goh, Janice

University of California, San Francisco
PII-009 - NOVEL IN VITRO TUBERCULOSIS ASSAYS AND THEIR UTILITY IN PREDICTING IN VIVO DRUG EFFICACY.
Janice Goh
Favorite
Gooey, Andrew
LB-007 - A POPULATION PHARMACOKINETIC/PHARMACODYNAMIC MODEL FOR CARFILZOMIB IN COMBINATION WITH IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA.
Andrew Gooey
Favorite
Goyal, Rahul

University of Maryland
PII-064 - MODELING MORTALITY OF PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION USING SUPERVISED MACHINE LEARNING.
Rahul Goyal
Favorite
Grant, Caroline

Mayo Clinic
PII-050 - PHARMACOGENOMIC-AUGMENTED DRUG THERAPY IN MAJOR DEPRESSIVE DISORDER: A SYSTEMATIC REVIEW OF GENES AND A CASE FOR ARTIFICIAL INTELLIGENCE-AIDED GENOME-WIDE PANEL DESIGN.
Caroline Grant
Favorite
Gronich, Naomi

Clalit Health Services, and Technion Faculty of Medicine
PI-003 - PDE5 INHIBITORS AND DEMENTIA RISK: A REAL-WORLD STUDY.
Naomi Gronich
Favorite
RWE-008 - PDE5 INHIBITORS AND DEMENTIA RISK: A REAL-WORLD STUDY.
Naomi Gronich
Favorite
H
Hahn, Erik

Pfizer
PI-013 - COMPARISON OF PREDICTED OVERALL SURVIVAL TO OBSERVED CLINICAL DATA IN PATIENTS WITH BRAF V600-MUTANT METASTATIC MELANOMA TREATED WITH ENCORAFENIB ALONE OR ENCORAFENIB + BINIMETINIB.
Erik Hahn
Favorite
Haj-Ibrahim , Houda
E-004 - EXTRAPOLATION OF EFFICACY OF A DEXTROAMPHETAMINE TRANSDERMAL SYSTEM (d-ATS) FROM PEDIATRIC (PED) TO ADULT POPULATIONS USING PHARMACOKINETIC (PK) MODELING.
Houda Haj-Ibrahim
Favorite
Hamilton, Riley

The University of Chicago
PI-024 - CHRONIC NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) USE INCREASES GASTRIC TOXICITY: A PHARMACOGENOMIC ANALYSIS.
Riley Hamilton
Favorite
Han, Xiaomei

US Food and Drug Administration
PII-068 - PHARMACOKINETIC AND PHARMACODYNAMIC MODELING OF OPIOID AND SEDATIVE/PSYCHOTROPIC DRUG EFFECTS ON VENTILATION AND PUPILLOMETRY.
Xiaomei Han
Favorite
Hartauer, Mattie

University of North Carolina at Chapel Hill
PII-095 - APPLICATION OF A PERMEABILITY-LIMITED MULTI-COMPARTMENT LIVER MODEL TO INVESTIGATE RIFAMPICIN-MEDIATED ZONAL INDUCTION OF HEPATIC OATP1B1 IN A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) FRAMEWORK.
Mattie Hartauer
Favorite
PWI-005 - APPLICATION OF A PERMEABILITY-LIMITED MULTI-COMPARTMENT LIVER MODEL TO INVESTIGATE RIFAMPICIN-MEDIATED ZONAL INDUCTION OF HEPATIC OATP1B1 IN A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) FRAMEWORK.
Mattie Hartauer
Favorite
Hohmann, Nicolas

National Center for Tumor Diseases
PI-017 - ELIGIBILITY CRITERIA OF EARLY PHASE ONCOLOGY TRIALS.
Nicolas Hohmann
Favorite
Hong, Eunjin

University of Southern California
PII-097 - PBPK MODELING OF LUNG TISSUE PREDICTS EFFICACY OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR WITH CONCOMITANT RIFABUTIN ADMINISTRATION.
Eunjin Hong
Favorite
PWI-001 - PBPK MODELING OF LUNG TISSUE PREDICTS EFFICACY OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR WITH CONCOMITANT RIFABUTIN ADMINISTRATION.
Eunjin Hong
Favorite
Huang, Robbie

Xeris Pharmaceuticals
LB-014 - POPULATION PHARMACOKINETIC ANALYSIS OF PHASE 1 SUBCUTANEOUS LEVOTHYROXINE FORMULATION (XP-8121).
Robbie Huang
Favorite
Hudson, Rachel

University of Utah
PII-120 - AN INTERIM PHARMACOKINETIC (PK) ANALYSIS OF CANNABINOIDS IN SERUM OF VOLUNTEERS RECEIVING COSMETIC HEMP EXTRACT VIA THE ORAL OR TOPICAL ROUTES.
Rachel Hudson
Favorite
Hughes, Emma

University of California, San Francisco
PT-007 - VALIDATING THE PROTECTIVE CONCENTRATION OF PIPERAQUINE FOR MALARIA PREVENTION IN PREGNANT UGANDAN WOMEN.
Emma Hughes
Favorite
Hunt, Porter

University of Utah
PT-001 - MAXIMUM LIKELIHOOD ESTIMATION OF RENAL TRANSPORTER ONTOGENY PROFILES FOR PEDIATRIC PBPK MODELING.
Porter Hunt
Favorite
Hwang, Sejung

Seoul National University College of Medicine and Hospital
PII-029 - THE EFFECTS OF RIFAMPICIN AS AN ORGANIC ANION TRANSPORTING POLYPEPTIDES INHIBITOR AND FEBUXOSTAT AS A BREAST CANCER RESISTANCE PROTEIN INHIBITOR ON PHARMACOKINETICS OF METHOTREXATE IN HEALTHY SUBJECTS.
Sejung Hwang
Favorite
I
Imperial, Marjorie Z.

University of California, San Francisco
PT-012 - POPULATION PHARMACOKINETICS OF ISONIAZID IN TBTC STUDY 31/ACTG A5349.
Marjorie Z. Imperial
Favorite
Inaba, Shinichi

Daiichi Sankyo Co., Ltd.
PII-036 - MASS BALANCE AND METABOLITE IDENTIFICATION OF VALEMETOSTAT AFTER A SINGLE ORAL ADMINISTRATION IN HEALTHY MALE SUBJECTS.
Shinichi Inaba
Favorite
Ishihara, Yugo

Oita University
PI-099 - INTERNATIONAL COMPARISON OF THE NUMBER OF PHASE 3 CLINICAL TRIALS FOR COVID-19.
Yugo Ishihara
Favorite
J
Jafari, Eissa

University of Florida
PI-097 - CHARACTERIZING ANTIHYPERTENSIVE MEDICATION USAGE IN APPARENT TREATMENT-RESISTANT HYPERTENSION (aTRH) PATIENTS WITHIN THE STATE OF FLORIDA USING ELECTRONIC HEALTH RECORD (EHR)-BASED DATA.
Eissa Jafari
Favorite
RWE-010 - CHARACTERIZING ANTIHYPERTENSIVE MEDICATION USAGE IN APPARENT TREATMENT-RESISTANT HYPERTENSION (aTRH) PATIENTS WITHIN THE STATE OF FLORIDA USING ELECTRONIC HEALTH RECORD (EHR)-BASED DATA.
Eissa Jafari
Favorite
Jani, Khushboo

St. John’s University
PI-075 - APPLICATION OF MINIMAL PHYSIOLOGICALLY BASED PHARMACOKINETIC/PHARMACODYNAMIC MODEL FOR INSULIN.
Khushboo Jani
Favorite
Jarugula, Praneeth

Bristol Myers Squibb
PII-070 - PHARMACOKINETIC/PHARMACODYNAMIC ANALYSIS OF APIXABAN TO DETERMINE DOSING REGIMENS FOR PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA OR LYMPHOBLASTIC LYMPHOMA TREATED WITH ASPARAGINASE: ANALYSIS FROM THE PREVAPIX STUDY.
Praneeth Jarugula
Favorite
Jogiraju, Vamshi

Gilead Sciences
PII-056 - LENACAPAVIR PHARMACOKINETICS AND DDI POTENTIAL WITH CO-ADMINISTERED ANTIRETROVIRALS IN PEOPLE WITH HIV.
Vamshi Jogiraju
Favorite
John, August

Mayo Clinic
PII-034 - INVESTIGATION OF DRUG COMBINATIONS IN CANCER THROUGH UNBIASED IDENTIFICATION OF RECURRING DRUG RESPONSE PATTERNS IN CELL LINES.
August John
Favorite
Jonsson, Fredrik

qPharmetra, LLC
PII-031 - LONGITUDINAL EFFICACY ANALYSIS OF THE SUBLINGUAL FILM FORMULATION OF DEXMEDETOMIDINE (BXCL501) FOR THE TREATMENT OF ACUTE AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR DISORDER.
Fredrik Jonsson
Favorite
Joshi, Tanvi

Vantage Research
PII-125 - DEVELOPMENT OF RHEUMATOID ARTHRITIS QSP MODEL FOR TRIAL SIMULATION AND PREDICTING RESPONSE TO NOVEL COMBINATIONS.
Tanvi Joshi
Favorite
K
Kandala, Bhargava

Merck & Co.
PII-024 - TRANSLATIONAL MODEL-BASED META-ANALYSIS - A POWERFUL QUANTITATIVE TOOL IN DEVELOPING VACCINES AGAINST SARS-COV-2 VARIANTS.
Bhargava Kandala
Favorite
Kandasamy, Murugesh

Indiana University
PII-016 - PHARMACOKINETICS OF SHIP1 INHIBITORS IN MICE: COMPARISON OF IN SILICO AND IN VIVO PHARMACOKINETICS.
Murugesh Kandasamy
Favorite
Kapitanov, Georgi

Applied BioMath
PI-095 - BLINATUMOMAB TRIMER FORMATION - INSIGHTS FROM A MECHANISTIC PKPD MODEL ON THE IMPLICATIONS FOR SWITCHING FROM INFUSION TO SUBCUTANEOUS DOSING REGIMEN IN ACUTE LYMPHOBLASTIC LEUKEMIA AND NON-HODGKIN’S LYMPHOMA.
Georgi Kapitanov
Favorite
Kareva, Irina

EMD Serono
PI-073 - INTEGRATED MODEL-BASED ANALYSIS UTILIZING CO-EXPRESSED CHECKPOINT INHIBITOR DATA TO INFORM THE RECOMMENDED DOSE FOR EXPANSION (RDE) OF ANTI-TIGIT MAB M6223.
Irina Kareva
Favorite
Kathman, Steven

Gilead Sciences
PII-076 - POPULATION PHARMACOKINETIC (PK)-PHARMACODYNAMIC (PD) MODELING OF VESATOLIMOD, A TLR7 AGONIST IN DEVELOPMENT FOR HIV CURE.
Steven Kathman
Favorite
Katragadda, Suresh

Sanofi
EP-018 - POPULATION PHARMACOKINETIC ANALYSIS OF RILZABRUTINIB IN HEALTHY SUBJECTS AND PATIENTS WITH PEMPHIGUS.
Suresh Katragadda
Favorite
Kaushal, Neeraj

Moderna Therapeutics, Inc.
PI-054 - DEVELOPMENT OF A PHARMACOKINETIC-PHARMACODYNAMIC MODEL FOR MRNA-0184, AN INVESTIGATIONAL MRNA THERAPEUTIC ENCODING HUMAN RELAXIN-2-VLK FOR THE TREATMENT OF HEART FAILURE.
Neeraj Kaushal
Favorite
Khwarg, Juyoung

Seoul National University College of Medicine and Hospital
PII-069 - PHARMACOKINETIC COMPARISON BETWEEN A FIXED-DOSE COMBINATION OF ATORVASTATIN/OMEGA-3 AND THE CORRESPONDING LOOSE COMBINATION IN HEALTHY KOREAN SUBJECTS.
Juyoung Khwarg
Favorite
Killam, Shayna

University of Montana
PT-029 - BUILDING A TELEHEALTH PHARMACOGENETIC TESTING PROGRAM IN RURAL AND PEDIATRIC PSYCHIATRY.
Shayna Killam
Favorite
Kim, Byungwook

Seoul National University Hospital
PII-073 - PHARMACOKINETICS AND PHARMACODYNAMICS OF EVOGLIPTIN IN END-STAGE RENAL DISEASE PATIENTS ON HEMODIALYSIS.
Byungwook Kim
Favorite
Kim, Dong Hyun

Kyung Hee University
PI-094 - A QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL OF SEPSIS-INDUCED AUGMENTED RENAL CLEARANCE.
Dong Hyun Kim
Favorite
Kim, Ha-Yeon

Chungbuk National University Hospital
PI-049 - COMPARISON OF THE ACID SUPPRESSION EFFECTS BETWEEN LOW-DOSE ESOMEPRAZOLE AND FAMOTIDINE IN HEALTHY SUBJECTS.
Ha-Yeon Kim
Favorite
PII-066 - PHARMACOKINETIC AND PHARMACODYNAMIC CHARACTERISTICS OF PELUBIPROFEN TROMETHAMINE VERSUS PELUBIPROFEN IN HEALTHY SUBJECTS.
Ha-Yeon Kim
Favorite
Kim, Hyun Chul

Seoul National University College of Medicine and Hospital
PII-018 - THE PHARMACODYNAMICS, PHARMACOKINETICS, AND SAFETY OF VUTIGLABRIDIN, A SYNTHETIC GLABRIDIN DERIVATIVE, AFTER MULTIPLE ADMINISTRATION IN OBESE SUBJECTS.
Hyun Chul Kim
Favorite
Kim, Jae Hoon

Chungnam National University Hospital
EP-031 - PHARMACOKINETIC INTERACTION OF OMEGA-3 FATTY ACID 4 G AND ATORVASTATIN 40 MG.
Jae Hoon Kim
Favorite
Kim, Kyeongmin

The Ohio State University
PI-070 - EXPOSURE-TARGETED MELPHALAN DOSING INDIVIDULIZATION IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS TRANSPLANT.
Kyeongmin Kim
Favorite
Kim, Ryunha

Inje University
EP-013 - DEVELOPMENT OF POPULATION PHARMACOKINETICS MODEL OF PYRAZINAMIDE AND OPTIMAL DOSE RECOMMENDATION FOR ELDERLY WITH DIABETES MELLITUS IN KOREAN TUBERCULOSIS PATIENTS.
Ryunha Kim
Favorite
Kim, Yoon Jin

Seoul National University Hospital
PII-015 - PHARMACOKINETICS AND PHARMACODYNAMICS OF ENAVOGLIFLOZIN, AN SGLT-2 INHIBITOR, IN TYPE 2 DIABETES PATIENTS WITH IMPAIRED RENAL FUNCTION.
Yoon Jin Kim
Favorite
Klomp, Sylvia

Leiden University Medical Center
PII-047 - INFLAMMATION DRIVEN INHIBITION OF CYP2C19 METABOLISM OF VORICONAZOLE IN THE TREATMENT OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS.
Sylvia Klomp
Favorite
Koh, JaeEun

Seoul National University College of Medicine and Hospital
PI-045 - COMPARATIVE PHARMACOKINETICS BETWEEN DA-2811, A DAPAGLIFLOZIN PRODRUG FORMULATION, AND CONVENTIONAL DAPAGLIFLOZIN TABLET.
JaeEun Koh
Favorite
Koldeweij, Charlotte

Radboud University Medical Center
PI-090 - PERCEIVED BARRIERS AND FACILITATORS FOR MODEL-INFORMED DOSING IN PREGNANCY AMONG HEALTHCARE PRACTITIONERS AND PREGNANT WOMEN: A QUALITATIVE STUDY.
Charlotte Koldeweij
Favorite
Koleske, Megan

University of California, San Francisco
LB-006 - EFFECTS OF ANTIOXIDANTS IN DRUGS PRODUCTS ON INTESTINAL DRUG TRANSPORTERS.
Megan Koleske
Favorite
Kotani, Naoki

Chugai Pharmaceutical Co., Ltd.
PII-042 - TRANSLATABILITY OF IN VITRO POTENCY TO CLINICALLY EFFICACIOUS EXPOSURE FOR MOLECULARLY TARGETED SMALL MOLECULE ONCOLOGY DRUGS.
Naoki Kotani
Favorite
Kurata, Akifumi

Daiichi Sankyo
PI-010 - A DDI STUDY TO EVALUATE THE EFFECT OF MULTIPLE ORAL ADMINISTRATION OF RIFAMPICIN ON THE PHARMACOKINETICS OF VALEMETOSTAT IN HEALTHY PARTICIPANTS.
Akifumi Kurata
Favorite
Kyler, Kathryn

Children's Mercy Kansas City
PT-005 - MAJOR POTENTIAL DRUG-DRUG INTERACTIONS AMONG MEDICAID-INSURED CHILDREN IN THE OUTPATIENT SETTING.
Kathryn Kyler
Favorite
L
Lagraauw, H. Maxime

qPharmetra, LLC
PII-100 - POPULATION PHARMACOKINETIC ANALYSIS OF THE SUBLINGUAL FILM FORMULATION OF DEXMEDETOMIDINE (BXCL501) IN HEALTHY VOLUNTEERS AND ADULTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER.
H. Maxime Lagraauw
Favorite
Lam, Inez

Johns Hopkins University
PT-011 - COMPUTATIONAL SYSTEMS PHARMACOLOGY OF ANTIBODY-DRUG CONJUGATES.
Inez Lam
Favorite
Larson, Thomas

Takeda Development Center Americas, Inc.
PI-055 - DOSE SELECTION FOR BRIGATINIB TO SUPPORT PEDIATRIC DEVELOPMENT.
Thomas Larson
Favorite
León, Cristhyne

Novadiscovery
LB-015 - A TRANSLATIONAL COMPUTATIONAL MODEL OF ALLERGEN CHALLENGE TO SUPPORT THE CLINICAL DEVELOPMENT OF AN INTRANASALLY ADMINISTERED BACTERIAL LYSATE IN MILD ASTHMA.
Cristhyne León
Favorite
Lee, Hyun Kyung

Seoul National University
PT-017 - CARDIOVASCULAR SAFETY OF CARFILZOMIB IN KOREA: RETROSPECTIVE COHORT STUDY USING A NATIONWIDE ADMINISTRATIVE CLAIM DATABASE.
Hyun Kyung Lee
Favorite
Lee, Jeayoon

Seoul National University
PII-079 - POPULATION PHARMACOKINETIC MODELING OF EVEROLIMUS AND INDIVIDUALIZED DOSING DEPENDING ON PROMISING COVARIATES IN LIVER TRANSPLANT RECIPIENTS.
Jeayoon Lee
Favorite
Lee, Moon Hee

Asan Medical Center
PII-067 - PHARMACOKINETIC AND PHARMACODYNAMIC MODELING ANALYSIS OF JPI-547 IN PATIENTS WITH ADVANCED SOLID TUMOR.
Moon Hee Lee
Favorite
Lee, Nora

LG Chem
PII-080 - POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODELING AND SIMULATION FOR TIGULIXOSTAT, A NOVEL XANTHINE OXIDASE INHIBITOR FOR THE TREATMENT OF GOUT WITH HYPERURICEMIA.
Nora Lee
Favorite
Le, Tien

University of North Carolina at Chapel Hill
PI-028 - EVALUATING THE IMPACT OF PROTON PUMP INHIBITOR USE ON CARDIOVASCULAR OUTCOMES IN PATIENTS RECEIVING CYP2C19 GENOTYPE GUIDED ANTIPLATELET THERAPY IN A REAL-WORLD SETTING.
Tien Le
Favorite
PWIII-005 - EVALUATING THE IMPACT OF PROTON PUMP INHIBITOR USE ON CARDIOVASCULAR OUTCOMES IN PATIENTS RECEIVING CYP2C19 GENOTYPE GUIDED ANTIPLATELET THERAPY IN A REAL-WORLD SETTING.
Tien Le
Favorite
Liang, Min

Moderna Therapeutics, Inc.
PI-082 - PLASMA METHYLMALONIC ACID CONCENTRATION IS POSITIVELY ASSOCIATED WITH METABOLIC DECOMPENSATION EVENTS IN PATIENTS WITH METHYLMALONIC ACIDEMIA.
Min Liang
Favorite
PII-106 - PLASMA 3-HYDROXYPROPIONIC ACID CONCENTRATION IS POSITIVELY ASSOCIATED WITH METABOLIC DECOMPENSATION EVENTS IN PATIENTS WITH PROPIONIC ACIDEMIA.
Min Liang
Favorite
Liao, Kai

Arcus Biosciences
PII-045 - USE OF A POPULATION PHARMACOKINETIC MODELLING AND SIMULATION APPROACH TO IDENTIFY FLAT DOSES OF DOMVANALIMAB IN PHASE 3 STUDIES.
Kai Liao
Favorite
Li, Dan

Merck & Co.
PII-025 - UNDERSTANDING THE PK/PD RELATIONSHIP FOR THE METALLO-BETA-LACTAMASE (MBL) INHIBITOR MK-3402 AND PRELIMINARY DOSE PROJECTION FOR PATIENTS WITH MDR GRAM-NEGATIVE INFECTIONS.
Dan Li
Favorite
Li, Jia

Takeda Development Center Americas, Inc.
PI-011 - CHARACTERIZING THE RELATIONSHIP BETWEEN CELLULAR KINETICS AND RESPONSE TO SUPPORT DOSING RECOMMENDATIONS FOR CD19-TARGETED 19(T2)28Z1XX CELL THERAPY.
Jia Li
Favorite
Li, Lang

The Ohio State University
PI-098 - THE MATERNAL AND PEDIATRIC PRECISION IN THERAPEUTICS (MPRINT) KNOWLEDGEBASE AND PORTAL.
Lang Li
Favorite
Lim, Hyeong-Seok

Asan Medical Center
PI-015 - DEVELOPMENT OF USER-FRIENDLY BAYESIAN PREDICTIVE PLATFORM FOR BLOOD BORON-10 PHARMACOKINETICS FOLLOWING INTRAVENOUS INFUSION OF [10B]L-4-BORONOPHENYLALANINE.
Hyeong-Seok Lim
Favorite
PII-090 - TRANSLATIONAL PHARMACOKINETIC-PHARMACODYNAMIC MODELING AND SIMULATION TO PREDICT EFFICACIOUS HUMAN DOSES FOR YH35324 (GI-301)
Hyeong-Seok Lim
Favorite
Lim, KyoungSoo

AstraZeneca
EP-008 - POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSIS OF TREMELIMUMAB 300 MG SINGLE DOSE COMBINED WITH DURVALUMAB 1500 MG EVERY 4 WEEKS (STRIDE) IN UNRESECTABLE HEPATOCELLULAR CARCINOMA.
KyoungSoo Lim
Favorite
Liu, Sihang

Bristol Myers Squibb
PII-061 - MODEL INFORMED DRUG DEVELOPMENT (MIDD) TO SUPPORT AN ALTERNATIVE NIVOLUMAB DOSE AND SCHEDULE FOR ADVANCED MELANOMA.
Sihang Liu
Favorite
Liu, Tao

US Food and Drug Administration
PI-086 - COMPARISON OF DISEASE CHARACTERISTICS IN ADULTS AND CHILDREN WITH TYPE 2 DIABETES MELLITUS: IMPLICATION FOR ANTIDIABETIC DRUG DEVELOPMENT IN CHILDREN.
Tao Liu
Favorite
Lo, Arthur

Global Blood Therapeutics
PII-062 - MODEL-BASED APPROACH TO SELECT THE DOSE REGIMEN OF GBT021601, A NEXT-GENERATION SICKLE HEMOGLOBIN POLYMERIZATION INHIBITOR, IN HEALTHY VOLUNTEERS AND PATIENTS WITH SICKLE CELL DISEASE.
Arthur Lo
Favorite
PWII-001 - MODEL-BASED APPROACH TO SELECT THE DOSE REGIMEN OF GBT021601, A NEXT-GENERATION SICKLE HEMOGLOBIN POLYMERIZATION INHIBITOR, IN HEALTHY VOLUNTEERS AND PATIENTS WITH SICKLE CELL DISEASE.
Arthur Lo
Favorite
M
Maas, Brian

Merck & Co.
LB-004 - MOLNUPIRAVIR EXPOSURE-RESPONSE OF CLINICAL OUTCOMES IN TREATMENT OF COVID-19.
Brian Maas
Favorite
Manting, Chiang

Bristol Myers Squibb
PI-058 - DRUG-DRUG INTERACTION POTENTIAL OF MAVACAMTEN WITH ORAL CONTRACEPTIVES: RESULTS FROM A CLINICAL PHARMACOKINETIC STUDY.
Chiang Manting
Favorite
Martin, James

University of Colorado Anschutz Medical Campus
PI-023 - CHARACTERISTICS OF PROVIDERS WHO RESPONDED TO PASSIVE CLINICAL DECISION SUPPORT ALERTS FOLLOWING PRE-EMPTIVE RETURN OF PHARMACOGENOMIC RESULTS.
James Martin
Favorite
PII-111 - EVALUATION OF SEX DIFFERENCES IN MEDICATION PRESCRIBING RECOMMENDATIONS AND OCCURRENCE OF ADVERSE EVENTS.
James Martin
Favorite
PWIII-003 - CHARACTERISTICS OF PROVIDERS WHO RESPONDED TO PASSIVE CLINICAL DECISION SUPPORT ALERTS FOLLOWING PRE-EMPTIVE RETURN OF PHARMACOGENOMIC RESULTS.
James Martin
Favorite
Mascelli, Mary Ann

Kyowa Kirin Co., Ltd.
PI-038 - APPLICATION OF MODELING AND SIMULATION TO EXTRAPOLATE THERAPEUTIC BUROSUMAB DOSING REGIMENS FOR SUBJECTS WITH PEDIATRIC TUMOR-INDUCED OSTEOMALCIA.
Mary Ann Mascelli
Favorite
Ma, Xiaotang

Bristol Myers Squibb
PI-102 - POST MARKETING COMMITMENT OR REQUIREMENT (PMC/R) FOR RECENT APPROVED DRUG PRODUCTS: SUMMARY FROM CLINICAL PHARMACOLOGY (CP) PERSPECTIVES.
Xiaotang Ma
Favorite
Mc Laughlin, Anna

Pharmetheus
PII-041 - POTENTIAL STRATEGIES TO OPTIMIZE CAR-T CELL EXPOSURE IN ABSENCE OF DOSE-EXPOSURE RELATIONSHIPS LEVERAGING CELL KINETIC/DYNAMIC MODELS.
Anna Mc Laughlin
Favorite
McComb, Mason

Amgen Inc.
PI-101 - AN OPEN-LABEL SINGLE-DOSE STUDY TO EVALUATE THE PHARMACOKINETICS OF SOTORASIB IN HEALTHY SUBJECTS AND SUBJECTS WITH MODERATE OR SEVERE HEPATIC IMPAIRMENT.
Mason McComb
Favorite
McIntire, Carter

Cincinnati Children's Hospital Medical Center
PII-117 - PIPERACILLINE PHARMACOKINETICS AND PHARMACODYNAMICS IN PEDIATRIC PATIENTS WHO RECEIVED HIGH FREQUENCY PIPERACILLIN/TAZOBACTAM DOSING DURING SURGERY.
Carter McIntire
Favorite
McNamee, Brian

AbbVie Inc.
PII-087 - THE EFFECT OF FOOD ON T3 AND T4 BIOAVAILABILITY AND THE DOSE PROPORTIONALITY OF ARMOUR THYROID.
Brian McNamee
Favorite
Mease, James

US Food and Drug Administration
PT-021 - PHARMACOKINETIC (PK) BASIS OF STATIN DRUG-DRUG INTERACTION (DDI) INFORMATION IN FDA LABELS.
James Mease
Favorite
Mehanna, Mai

University of Florida
EP-002 - INTEGRATED METABOLOMICS ANALYSIS REVEALS MECHANISTIC INSIGHTS INTO THE ANCESTRAL DIFFERENCES IN PLASMA RENIN ACTIVITY AMONG PATIENTS WITH HYPERTENSION AND THIAZIDE DIURETICS BLOOD PRESSURE LOWERING EFFECTS.
Mai Mehanna
Favorite
Mehta, Jaydeep

Janssen Research and Development LLC
PI-100 - THE DRUG-DRUG INTERACTION (DDI) EFFECT OF STEADY STATE ITRACONAZOLE EXPOSURE ON SINGLE DOSE PHARMACOKINETICS (PK) OF LAZERTINIB.
Jaydeep Mehta
Favorite
Mehta, Parsshava

University of Florida
PT-023 - DEVELOPMENT OF INTRANASAL PHYSIOLOGICALLY BASED NOSE TO BRAIN MODEL AND ITS APPLICATION TO CHARACTERIZE IN NEUROEPO ABSORPTION VIA NASAL ROUTE AND DISTRIBUTION TO LUMBAR CSF IN HEALTHY NON-HUMAN PRIMATES (CYANOMOLGUS MONKEY).
Parsshava Mehta
Favorite
Meiman, Darius

Indiana University
PII-099 - PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL TO ASSESS THE DRUG-DRUG-GENE INTERACTION POTENTIAL OF BELZUTIFAN IN COMBINATION WITH CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN HEALTHY VOLUNTEERS.
Darius Meiman
Favorite
Mendell, Jeanne

Regeneron Pharmaceuticals, Inc.
PII-074 - PHARMACOKINETICS OF MIBAVADEMAB (MIBA) IN HEALTHY PARTICIPANTS: RESULTS FROM A RANDOMIZED, PHASE 1, TWO-PART, FIRST-IN-HUMAN STUDY.
Jeanne Mendell
Favorite
Miller, Emily

Virginia Commonwealth University
PII-030 - IMPACT OF COMORBID PAIN, PSYCHIATRIC DIAGNOSES, AND SUBSTANCE USE DISORDERS ON OPIOID USE DISORDER TREATMENT IN PERSONS WITH AND WITHOUT HIV.
Emily Miller
Favorite
RWE-003 - IMPACT OF COMORBID PAIN, PSYCHIATRIC DIAGNOSES, AND SUBSTANCE USE DISORDERS ON OPIOID USE DISORDER TREATMENT IN PERSONS WITH AND WITHOUT HIV.
Emily Miller
Favorite
Mir, Nabiel

The University of Chicago
PII-127 - GERIATRIC REMOTE INITIATIVE (GeRI): IMPLEMENTING REMOTE ASSESSMENTS OF TOXICITY AND FRAILTY FOR OLDER ADULTS WITH CANCER.
Nabiel Mir
Favorite
RWE-004 - GERIATRIC REMOTE INITIATIVE (GeRI): IMPLEMENTING REMOTE ASSESSMENTS OF TOXICITY AND FRAILTY FOR OLDER ADULTS WITH CANCER.
Nabiel Mir
Favorite
Mizuno, Kana

Cincinnati Children's Hospital Medical Center
PI-060 - ECULIZUMAB COMPLEMENT-MEDIATED PK/PD MODEL-INFORMED SIMULATIONS REVEAL THE NEED FOR ALTERNATIVE DOSING REGIMENS DURING MAINTENANCE THERAPY FOR STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (TA-TMA).
Kana Mizuno
Favorite
Molla, Hanna

The University of Chicago
PII-033 - THE EFFECTS OF AN ACUTE ORAL DOSE OF METHAMPHETAMINE ON NEURAL ACTIVATION DURING PERFORMANCE ON A MONETARY REWARD TASK IN HEALTHY ADULTS.
Hanna Molla
Favorite
Morcos, Peter

Bayer
PII-075 - PHARMACOMETRICS (PMX) APPROACH TO SUPPORT PEDIATRIC DOSING FOR THE PAN-PI3K INHIBITOR COPANLISIB IN CHILDREN AND ADOLESCENTS WITH RELAPSED/REFRACTORY SOLID TUMORS.
Peter Morcos
Favorite
Movafagh, Shahrzad

Sheanndoah University
EP-010 - HYPOXIA INDUCIBLE FACTOR-1A POLYMORPHISMS ASSOCIATED WITH ADVANCED CHRONIC KIDNEY DISEASE.
Shahrzad Movafagh
Favorite
Mukker, Jatinder

EMD Serono
PI-071 - HOLISTIC INTEGRATION OF POPULATION PHARMACOKINETICS, PHARMACODYNAMICS AND SAFETY TO DEFINE RECOMMENDED DOSE FOR EXPANSION OF ATR INHIBITOR, M1774: AN ILLUSTRATION OF MODEL-INFORMED EARLY ONCOLOGY DRUG DEVELOPMENT.
Jatinder Mukker
Favorite
Murphy, William

University of North Carolina at Chapel Hill
PII-027 - LEVERAGING MACHINE LEARNING (ML) TO QUANTIFY CHANGES IN CELLULAR LOCALIZATION AND ZONAL DISTRIBUTION OF TRANSPORTERS IN LIVER TISSUE FROM PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD).
William Murphy
Favorite
N
Nayak, Satyaprakash

Pfizer
PII-104 - INDIVIDUAL DOSE OPTIMIZATION FOR SOMATROGON BY MODELING AND SHINY INTERFACE.
Satyaprakash Nayak
Favorite
Neal, Reem

Mayo Clinic
PT-026 - TRANSCRIPTOMIC PROFILING OF PTRPD KNOCK-DOWN IN HUMAN IPSC-DERIVED NEURONS REVEALED A ROLE IN ALCOHOL USE DISORDER DRUG TREATMENT RESPONSE.
Reem Neal
Favorite
Nepal, Mahesh

The Ohio State University
PII-028 - PACIFIC BLUE DERIVATIVES OF PACLITAXEL AS FLUORESCENT PROBES OF ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B (OATP1B) TRANSPORTERS.
Mahesh Nepal
Favorite
Nguyen, Duyen

US Food and Drug Administration
PI-084 - EXPLORATION FOR EXCLUSION OF FEMALES OF REPRODUCTIVE POTENTIAL AS A BIOEQUIVALENCE STUDY POPULATION IN PRODUCT-SPECIFIC GUIDANCES FOR GENERIC DRUG DEVELOPMENT.
Duyen Nguyen
Favorite
PWIV-001 - EXPLORATION FOR EXCLUSION OF FEMALES OF REPRODUCTIVE POTENTIAL AS A BIOEQUIVALENCE STUDY POPULATION IN PRODUCT-SPECIFIC GUIDANCES FOR GENERIC DRUG DEVELOPMENT.
Duyen Nguyen
Favorite
Nguyen, James

Washington State University
PI-040 - ASSESSING THE GOLDENSEAL-METFORMIN PHARMACOKINETIC INTERACTION IN TYPE 2 DIABETICS.
James Nguyen
Favorite
Nguyen, Thomas

University at Buffalo
PT-004 - PROSPECTIVE VALIDATION OF MAXIMUM A POSTERIORI-BAYESIAN ESTIMATION OF TACROLIMUS EXPOSURE IN STABLE KIDNEY TRANSPLANT RECIPIENTS.
Thomas Nguyen
Favorite
Noormohamed, Nadia

GlaxoSmithKline
PI-006 - PHARMACOKINETICS AND SAFETY OF SINGLE-DOSE BEPIROVERSIN IN ADULTS WITH MODERATE HEPATIC IMPAIRMENT AND HEALTHY MATCHED CONTROLS (B-ASSURED).
Nadia Noormohamed
Favorite
PII-023 - RISK OF QT PROLONGATION WITH OLIGONUCLEOTIDES: A REVIEW OF PUBLISHED EVIDENCE.
Nadia Noormohamed
Favorite
Novakovic, Jasmina

Simulations Plus Inc
LB-013 - PHYSIOLOGICALLY BASED ABSORPTION AND PHARMACOKINETIC MODEL FOR RIVOCERANIB AND ITS MAIN METABOLITE TO ASSESS POTENTIAL CYP3A4-MEDIATED DDI RISK.
Jasmina Novakovic
Favorite
O
Oh, Jung Jin

Seoul National University Hospital
PI-004 - SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF A NOVEL MACROCYCLIC GADOLINIUM-BASED CONTRAST AGENT, HNP-2006, AFTER A SINGLE INTRAVENOUS ADMINISTRATION IN HEALTHY SUBJECTS.
Jung Jin Oh
Favorite
P
Pallikonda Chakravarthy, Seshasai

Vantage Research
PI-096 - DEVELOPMENT OF IMMUNO-ONCOLOGY (IO) QSP PLATFORM MODEL FOR EFFICACY PREDICTION OF CHECKPOINT INHIBITORS (CPI) AND ADC COMBINATION THERAPY IN PHASE II/III CLINICAL TRIALS.
Seshasai Pallikonda Chakravarthy
Favorite
Park, Hyun Jin

Seoul National University
PII-084 - POPULATION PHARMACOKINETICS OF MYCOPHENOLATE MOFETIL IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS.
Hyun Jin Park
Favorite
Park, Seok Jun

Kyung Hee University
PII-109 - PATTERNS OF USING ANTIDIABETIC MEDICATIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN KOREA WITH AND WITHOUT CHRONIC KIDNEY DISEASES: MULTI-INSTITUTIONAL, REAL-WORLD DATA ANALYSIS USING THE OMOP COMMON DATA MODEL.
Seok Jun Park
Favorite
RWE-009 - PATTERNS OF USING ANTIDIABETIC MEDICATIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN KOREA WITH AND WITHOUT CHRONIC KIDNEY DISEASES: MULTI-INSTITUTIONAL, REAL-WORLD DATA ANALYSIS USING THE OMOP COMMON DATA MODEL.
Seok Jun Park
Favorite
Patel, Anu

University of California, San Francisco
PII-091 - TRANSLATIONAL TOOL FOR PREDICTING THE EARLY BACTERICIDAL ACTIVITY OF SUTEZOLID FOR THE TREATMENT OF TUBERCULOSIS.
Anu Patel
Favorite
PT-010 - PREDICTING LINEZOLID-INDUCED HEMATOLOGIC TOXICITIES IN REAL-WORLD PATIENTS WITH HYBRID MODELING.
Anu Patel
Favorite
RWE-007 - PREDICTING LINEZOLID-INDUCED HEMATOLOGIC TOXICITIES IN REAL-WORLD PATIENTS WITH HYBRID MODELING.
Anu Patel
Favorite
Patel, Yogesh

Sarepta Therapeutics, Inc.
PI-066 - ETEPLIRSEN, GOLODIRSEN, AND CASIMERSEN SHOW CONSISTENT CLINICAL PHARMACOLOGY PROPERTIES FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY.
Yogesh Patel
Favorite
Pavia, Kathryn

Cincinnati Children's Hospital Medical Center
PI-085 - CEFEPIME PHARMACOKINETICS IN CRITICALLY ILL CHILDREN UNDERGOING CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT).
Kathryn Pavia
Favorite
Paydary, Koosha

The University of Chicago
PI-036 - AN IN SILICO SIMULATION STUDY OF EXTENDED INTERVAL DOSING OF ATEZOLIZUMAB USING POPULATION PHARMACOKINETICS.
Koosha Paydary
Favorite
Philips, Trudy

Mayo Clinic
PT-020 - FUNCTIONAL CHARACTERIZATION OF ELAVL2 REVEALED THE ROLE OF POST-TRANSCRIPTIONAL REGULATION IN PSYCHIATRIC DISORDERS AND ANTIDEPRESSANT TREATMENT RESPONSE.
Trudy Philips
Favorite
Piscitelli, Joseph

Pfizer
PI-061 - EFFECT OF A MODERATE CYP3A4 INDUCER ON ENCORAFENIB IN COMBINATION WITH BINIMETINIB IN PATIENTS WITH BRAF V600-MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS.
Joseph Piscitelli
Favorite
Pollinzi, Angela

University of Toronto
PII-118 - PROTEOMIC- AND BIOINFORMATIC- BASED CHARACTERIZATION OF A PRECLINICAL RODENT MODEL OF PREECLAMPSIA.
Angela Pollinzi
Favorite
Poweleit, Ethan

University of Cincinnati
PI-035 - A POPULATION PHARMACOKINETIC ANALYSIS OF ESCITALOPRAM AND THE EFFECT OF CYP2C19 ON CLEARANCE IN CHILDREN AND ADOLESCENTS.
Ethan Poweleit
Favorite
Powell, Nicholas

Indiana University
PI-029 - EVALUATION OF THE G6PD VARIANT C.376A>G ACTIVITY IN ALL OF US.
Nicholas Powell
Favorite
Q
Qian, Yuli

AbbVie Inc.
PI-091 - PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND TOLERABILITY OF CEDIROGANT FOLLOWING SINGLE AND MULTIPLE DOSES IN JAPANESE AND CHINESE HEALTHY VOLUNTEERS.
Yuli Qian
Favorite
PII-114 - PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF UPADACITINIB IN CHILDREN WITH ATOPIC DERMATITIS.
Yuli Qian
Favorite
Quinney, Sara

Indiana University
PI-063 - EFFECT OF CYP3A AND CYP2D6 GENOTYPES ON THE PHARMACOKINETICS OF OXYCODONE IN CHILDREN.
Sara Quinney
Favorite
PWIII-004 - EFFECT OF CYP3A AND CYP2D6 GENOTYPES ON THE PHARMACOKINETICS OF OXYCODONE IN CHILDREN.
Sara Quinney
Favorite
R
Rademeyer, Kara

Virginia Commonwealth University
EP-027 - EXAMINING THE REGIONAL IMPACT OF FENTANYL ON INFLAMMATORY MEDIATORS WITHIN THE BRAIN IN THE SETTING OF HIV.
Kara Rademeyer
Favorite
Ramamoorthy, Anuradha

US Food and Drug Administration
PII-108 - HUMAN RADIOLABELED MASS BALANCE STUDIES SUPPORTING NEW DRUGS APPROVAL BY THE FDA BETWEEN 2019 TO JUNE 2022.
Anuradha Ramamoorthy
Favorite
Regan, Sean

Gilead Sciences
PI-007 - PHARMACOKINETICS OF REMDESIVIR AND ITS METABOLITES IN PARTICIPANTS WITH MODERATE AND SEVERE HEPATIC IMPAIRMENT.
Sean Regan
Favorite
Remaily, Bryan

The Ohio State University
PII-008 - FC RECEPTOR MODULATION AND POTENTIAL IMPACT ON CLEARANCE OF IMMUNE CHECKPOINT INHIBITORS IN CANCER CACHEXIA.
Bryan Remaily
Favorite
Ren, Tianjing

University at Buffalo
PI-067 - EVALUATION OF CREATININE-BASED RENAL FUNCTION ESTIMATION EQUATIONS BY PHARMACOMETRIC ANALYSIS FOR ANTIBIOTICS.
Tianjing Ren
Favorite
Rezaei, Leyla

University of Iowa
PII-060 - METHOTREXATE POPULATION PHARMACOKINETICS IN PATIENTS WITH PRIMARY CNS LYMPHOMA: A SINGLE INSTITUTION RETROSPECTIVE STUDY.
Leyla Rezaei
Favorite
Ridge, Sarah

US Food and Drug Administration
PII-110 - US FDA POSTMARKETING REQUIREMENTS AND COMMITMENTS RELATED TO DRUG DISPOSITION IN LACTATION AND PREGNANCY.
Sarah Ridge
Favorite
Rispoli, Paola

University of Trieste
EP-025 - INDUCED PLURIPOTENT STEM CELLS (IPSCS) AS A MODEL TO STUDY THIOPURINE INDUCED PANCREATITIS: PERSONALIZATION OF THERAPY IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
Paola Rispoli
Favorite
Rizk, Matthew

Merck & Co.
LB-005 - MOLNUPIRAVIR EXPOSURE-RESPONSE RELATIONSHIPS FOR CLINICAL OUTCOMES, VIROLOGY, AND MECHANISM OF ACTION BIOMARKERS ARE CONSISTENT IN TREATMENT OF COVID-19.
Matthew Rizk
Favorite
Rodriguez Vera, Leyanis

University of Florida
PI-079 - LEVERAGING PBPK DDI APPLICATION TO ENLIGHTEN THE MECHANISMS OF THE INTERACTION BETWEEN PHENYTOIN AND OMEPRAZOLE AND POTENTIAL IMPACT IN EPILEPTIC PATIENTS.
Leyanis Rodriguez Vera
Favorite
Ryu, Hyunwook

Seoul National University Hospital
PI-048 - COMPARISON OF PHARMACOKINETICS AND PHARMACODYNAMICS OF HIP1802 AND NEXIUM®: A RANDOMIZED, OPEN-LABEL, MULTIPLE DOSE, CROSSOVER TRIAL.
Hyunwook Ryu
Favorite
S
Salah, Lana

University of Colorado Anschutz Medical Campus
PII-021 - QUANTIFYING THE EFFECTS OF ALCOHOL USE ON DRIED BLOOD SPOT CONCENTRATIONS OF SOFOSBUVIR’S ACTIVE METABOLITE, 007-TP, IN PERSONS WITH HEPATITIS C USING PHOSPHATIDYLETHANOL AS AN OBJECTIVE BIOMARKER OF ALCOHOL CONSUMPTION.
Lana Salah
Favorite
Salem, Ahmed

University of Maryland Baltimore
PT-016 - POPULATION PHARMACOKINETIC MODELING TO GUIDE THE OPTIMAL DOSING FOR UNFRACTIONATED HEPARIN IN PEDIATRICS REQUIRING EXTRACORPOREAL MEMBRANE OXYGENATION.
Ahmed Salem
Favorite
Salem, Farzaneh

GlaxoSmithKline
PII-116 - PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING FOR DEVELOPMENT AND APPLICATIONS OF A VIRTUAL CELIAC DISEASE POPULATION USING FELODIPINE AS A MODEL DRUG.
Farzaneh Salem
Favorite
PWI-004 - PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING FOR DEVELOPMENT AND APPLICATIONS OF A VIRTUAL CELIAC DISEASE POPULATION USING FELODIPINE AS A MODEL DRUG.
Farzaneh Salem
Favorite
Salguero B, Maria

The University of Chicago
PII-119 - THE IMPACT OF PARENT-OF-ORIGIN ON CHILDHOOD GROWTH TRAJECTORIES AND SULFONYLUREAS USE IN CHILDREN WITH HNF1A-MODY IN THE U.S. MONOGENIC DIABETES REGISTRY.
Maria Salguero B
Favorite
RWE-011 - THE IMPACT OF PARENT-OF-ORIGIN ON CHILDHOOD GROWTH TRAJECTORIES AND SULFONYLUREAS USE IN CHILDREN WITH HNF1A-MODY IN THE U.S. MONOGENIC DIABETES REGISTRY.
Maria Salguero B
Favorite
Salimgareeva, Diana

Bashkir State Medical University
EP-022 - SELECTION OF COMPARISON DRUGS FOR ASSESSING THE CARDIAC PROTECTIVE PROPERTIES OF DRUG CANDIDATES.
Diana Salimgareeva
Favorite
Sano, Yamato

Pfizer R&D Japan
PI-039 - APPLICATION OF POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC MODELING TO SUPPORT DOSAGE REGIMEN OF FESOTERODINE IN PEDIATRICS WITH NEUROLOGICAL DETRUSOR OVERACTIVITY.
Yamato Sano
Favorite
Sathe, Abhishek

Gilead Sciences
PII-082 - POPULATION PHARMACOKINETICS (POPPK) OF SACITUZUMAB GOVITECAN (SG) IN PATIENTS (PTS) WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER (MBC) OR OTHER SOLID TUMORS.
Abhishek Sathe
Favorite
Schaller, Stephan

esqLABS GmbH
PI-080 - LEVERAGING PBPK-BASED ANALYSIS TO SUPPORT AN ADAPTIVE TRIAL DESIGN IN CHILDREN.
Stephan Schaller
Favorite
Schmith, Virginia (Ginny)

Schmith PK/PD Consulting LLC
PII-088 - THE EFFECT OF UGT INHIBITION ON THE PHARMACOKINETICS OF ECOPIPAM AND ITS METABOLITES.
Virginia (Ginny) Schmith
Favorite
Scholz, Erin

GlaxoSmithKline
PI-074 - A PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL EVALUATING THE DRUG-DRUG INTERACTION (DDI) POTENTIAL BETWEEN LAMOTRIGINE (LMT) AND ACETAMINOPHEN (APAP).
Erin Scholz
Favorite
Seo, Byeongjun

Cipherome, Inc
PI-022 - ANALYSIS OF TICAGRELOR AND PRASUGREL CORRELATION WITH CYP2C19 GENETIC VARIANTS AS ALTERNATIVE DRUGS FOR CLOPIDOGREL.
Byeongjun Seo
Favorite
Shabnaz, Samia

University of Florida
PII-052 - PROTEOMIC ANALYSIS OF CARFILZOMIB (CFZ) RELATED HEART FAILURE IN MULTIPLE MYELOMA (MM) PATIENTS FROM PROSPECTIVE STUDY OF CARDIAC EVENTS DURING PROTEASOME INHIBITOR THERAPY (PROTECT) STUDY.
Samia Shabnaz
Favorite
Shahin, Mohamed

Pfizer Global Research and Development
PI-047 - COMPARISON OF PATIENT-CENTRIC MICROSAMPLING VS. TRADITIONAL BLOOD SAMPLING FOR PHARMACOKINETIC ANALYSIS OF ABROCITINIB.
Mohamed Shahin
Favorite
Shahraz, Azar

AstraZeneca
PI-033 - A MECHANISTIC PK/PD MODEL OF AZD0171 (ANTI-LIF) TO SUPPORT PHASE 2 DOSE SELECTION.
Azar Shahraz
Favorite
PII-055 - INVESTIGATING THE EFFECT OF INFORMATIVE CENSORING ON THE KAPLAN-MEIER ESTIMATE OF ENDPOINTS IN ONCOLOGY CLINICAL TRIALS.
Azar Shahraz
Favorite
Shah, Shruti

GlaxoSmithKline
PII-124 - APPLICATION OF MACHINE LEARNING (ML) ON QSP VIRTUAL PATIENT POPULATION (VPOP) FOR IDENTIFICATION OF BIOMARKERS OF RESPONSE AND FOR SELECTION OF PRE-CONDITIONING REGIMEN FOR ENGINEERED T-CELL (ET-CELL) THERAPY.
Shruti Shah
Favorite
PWII-005 - APPLICATION OF MACHINE LEARNING (ML) ON QSP VIRTUAL PATIENT POPULATION (VPOP) FOR IDENTIFICATION OF BIOMARKERS OF RESPONSE AND FOR SELECTION OF PRE-CONDITIONING REGIMEN FOR ENGINEERED T-CELL (ET-CELL) THERAPY.
Shruti Shah
Favorite
Shakhnovich, Valentina

University of Missouri-Kansas City
PII-112 - MAGNETIC RESONANCE IMAGE-BASED ESTIMATES OF HEPATIC BLOOD FLOW IN CHILDREN WITH AND WITHOUT OBESITY; IMPLICATIONS FOR PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELS.
Valentina Shakhnovich
Favorite
PWI-003 - MAGNETIC RESONANCE IMAGE-BASED ESTIMATES OF HEPATIC BLOOD FLOW IN CHILDREN WITH AND WITHOUT OBESITY; IMPLICATIONS FOR PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELS.
Valentina Shakhnovich
Favorite
Sharma, Jyoti

Sanofi
PII-098 - PBPK MODELING TO ASSESS DRUG-DRUG INTERACTION POTENTIAL OF VENGLUSTAT WITH CYP3A INHIBITORS.
Jyoti Sharma
Favorite
Shaul, Chanan

Shaary-Zedek Medical Center, Hadassha Medical Center
PII-086 - QUANTITATIVE EFFECT OF CYP2C9 INDUCTION BY DICLOXACILLIN ON THE NARROW THERAPEUTIC DRUGS: PHENYTOIN AND WARFARIN.
Chanan Shaul
Favorite
Shi, Alan

University of Southern California
PI-081 - ELEXACAFTOR/TEZACAFTOR/IVACAFTOR (ETI) -INDUCED REACTIVE OXYGEN SPECIES (ROS) PRODUCTION IN HEPG2 CELLS: A POTENTIAL MECHANISM OF DRUG-INDUCED LIVER INJURY (DILI)
Alan Shi
Favorite
Shi, Jian

Bristol Myers Squibb
PI-041 - BENEFIT-RISK OF FLAT-DOSING OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN THORACIC CANCER IMMUNOTHERAPY (1L METASTATIC NON-SMALL-CELL LUNG CANCER AND 1L UNRESECTABLE MALIGNANT PLEURAL MESOTHELIOMA).
Jian Shi
Favorite
Shimamoto, Yuko

Osaka University, National Cerebral and Cardiovascular
EP-017 - MODEL-INFORMED VANCOMYCIN DOSING TO ADDRESS DELAYED RENAL MATURATION IN INFANTS AND YOUNG CHILDREN WITH CONGENITAL HEART DISEASE.
Yuko Shimamoto
Favorite
Simental, Paul

University of California, San Diego
PI-103 - EVALUATING THE CONSISTENCY AND EXTENT OF IMMUNOGENICITY REPORTING FOR RECENTLY APPROVED BIOLOGICS.
Paul Simental
Favorite
Simeon, Segolene

University of California, San Francisco
PT-022 - OPTIMIZING LUMEFANTRINE DOSING IN YOUNG CHILDREN USING REAL WORLD DATA AND PHARMACOKINETIC/PHARMACODYNAMIC SIMULATIONS.
Segolene Simeon
Favorite
RWE-006 - OPTIMIZING LUMEFANTRINE DOSING IN YOUNG CHILDREN USING REAL WORLD DATA AND PHARMACOKINETIC/PHARMACODYNAMIC SIMULATIONS.
Segolene Simeon
Favorite
Singh, Aman

Takeda Development Center Americas, Inc.
PII-003 - INTEGRATED CELLULAR KINETIC (CK) – PHARMACODYNAMIC (PD) ANALYSIS FOR FIRST IN HUMAN DOSE-ESCALATION STUDY OF TAK-102: A GPC3 TARGETED AUTOLOGOUS CAR-T CELLS ARMORED WITH IL-7 AND CCL19.
Aman Singh
Favorite
Somani, Roopali

Nizam's Institute of Medical Sciences
EP-004 - A SINGLE CENTRE, PROSPECTIVE STUDY TO EVALUATE THE EFFECT OF DOUBLE CARBAPENEM BASED COLISTIN THERAPY VERSUS BEST AVAILABLE THERAPY FOR THE TREATMENT OF CARBAPENEM RESISTANT ENTEROBACTERIACEAE AT A TERTIARY CARE HOSPITAL IN INDIA.
Roopali Somani
Favorite
Song, Yang

Horizon Therapeutics
PII-071 - PHARMACOKINETICS (PK) OF HZN-825, A SMALL MOLECULE SELECTIVE ANTAGONIST OF LPAR1, AND THE EFFECT OF FOOD IN HEALTHY ADULT SUBJECTS.
Yang Song
Favorite
Sorour, Mohammed

Temple University
PII-102 - PREDICTION OF DRUG-DRUG INTERACTIONS (DDI) WITH A MODERATE CYP3A INDUCER: DEVELOPMENT AND VALIDATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL OF RIFABUTIN.
Mohammed Sorour
Favorite
Srinivas, Nithya

Sage Therapeutics, Inc.
PII-093 - ZURANOLONE, A NOVEL GABAA POSITIVE ALLOSTERIC MODULATOR, DOES NOT PROLONG THE QT INTERVAL.
Nithya Srinivas
Favorite
Stancil, Stephani

Children's Mercy Kansas City
PII-006 - EARLY PHARMACODYNAMIC BIOMARKER DEVELOPMENT IN ADOLESCENTS WITH EATING DISORDERS.
Stephani Stancil
Favorite
Staples, Jack

University of Montana
PI-021 - A RETROSPECTIVE GENOME-WIDE ASSOCIATION STUDY OF ANTIPSYCHOTIC DRUG RESPONSE IN PEDIATRIC PATIENTS WITH PSYCHIATRIC ILLNESS IN A RURAL HEALTHCARE SETTING.
Jack Staples
Favorite
Stevenson, James

Johns Hopkins University
PI-025 - DOCUMENTATION OF RESULTS AND MEDICATION PRESCRIBING AFTER COMBINATORIAL PSYCHIATRIC PHARMACOGENETIC TESTING.
James Stevenson
Favorite
Stitt, Gideon

Children's Hospital of Philadelphia
PII-077 - POPULATION PHARMACOKINETIC MODELING AND SIMULATION OF TRANEXAMIC ACID IN ADULTS TRAUMA PATIENTS.
Gideon Stitt
Favorite
Strotmann, Rainer

Merck KGaA
PII-058 - LOW SENSITIVITY OF TEPOTINIB TO DRUG-DRUG INTERACTIONS WITH CYP3A4 AND P-GP MODULATORS.
Rainer Strotmann
Favorite
Su, Mei-Chi

Takeda Development Center Americas Inc.
PII-002 - DEVELOPMENT OF A MULTISCALE MECHNISM-BASED CELLULAR KINETIC-PHARMACODYNAMIC (CK-PD) MODEL FOR DUAL-TARGETED BICISTRONIC CAR-T CELL THERAPY.
Mei-Chi Su
Favorite
T
Taheri, Hanieh

The Ohio State University
PT-019 - ROLE OF ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B (OATP1B) IN HEPATIC UPTAKE AND ADVERSE EFFECTS OF AROMATASE INHIBITORS (AIS).
Hanieh Taheri
Favorite
Tanaka, Ryota

Oita University Hospital
LB-001 - POSITIVE CORRELATION BETWEEN ORGANIC ANION TRANSPORTER 1B FUNCTION INDICATED BY PLASMA CONCENTRATION OF COPROPORPHYRIN-I AND BLOOD CONCENTRATION OF CYCLOSPORIN A IN REAL-WORLD PATIENTS.
Ryota Tanaka
Favorite
Tang, Albert

Thomas Jefferson High School for Science and Technology
EP-026 - MACHINE LEARNING FOR PHARMACOKINETIC/PHARMACODYNAMIC MODELING.
Albert Tang
Favorite
Tanna, Rakshit

Washington State University
PT-028 - CLINICAL ASSESSMENT OF THE DRUG INTERACTION POTENTIAL OF THE PSYCHOTROPIC NATURAL PRODUCT KRATOM (MITRAGYNA SPECIOSA).
Rakshit Tanna
Favorite
Tan, Shawn Pei Feng

University of Manchester
PI-077 - DEVELOPMENT AND VERIFICATION OF A PYRIDOXIC ACID PBPK MODEL TO EVALUATE BIOMARKER INFORMED ORGANIC ANION TRANSPORTERS (OAT) 1 AND 3 INHIBITION.
Shawn Pei Feng Tan
Favorite
Tantawy, Marwa

University of Florida
PII-049 - MIRNA-125A ASSOCIATION WITH CARFILZOMIB-RELATED CARDIOVASCULAR ADVERSE EVENTS IN MULTIPLE MYELOMA PATIENTS: PROSPECTIVE OBSERVATION OF CARDIAC SAFETY WITH PROTEASOME INHIBITOR (PROTECT) STUDY.
Marwa Tantawy
Favorite
Taylor, Zachary

Cincinnati Children's Hospital Medical Center
PII-044 - UNDERSTANDING METHOTREXATE CONCENTRATIONS AND ASSOCIATED TOXICITIES TO GUIDE SUPPORTIVE CARE IN PATIENTS WITH NON-HODGKIN LYMPHOMA (NHL).
Zachary Taylor
Favorite
Tian, Dandan

Eli Lilly and Company
PII-101 - PREDICTING CLINICAL EFFECTS OF CYP3A4 PERPETRATORS ON PIRTOBRUTINIB PHARMACOKINETICS USING PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELLING.
Dandan Tian
Favorite
Tiley, Jacqueline

University of North Carolina at Chapel Hill
PII-026 - BILE ACIDS AS POTENTIAL BIOMARKERS TO ASSESS LIVER IMPAIRMENT IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD).
Jacqueline Tiley
Favorite
Tung, Pham My

Inje University
EP-011 - METABOLIC PROFILE INVESTIGATION REVEALS WIDE VARIABILITY IN THE EXPOSURE OF ISONIAZID AND ITS HEPATOTOXIC METABOLITES IN TUBERCULOSIS PATIENTS.
Pham My Tung
Favorite
U
Urdy, Séverine

Novadiscovery
LB-016 - EFFECTIVENESS OF HIGH DOSE VERSUS STANDARD DOSE INFLUENZA VACCINES IN OLDER ADULTS : INSIGHTS FROM A MULTI-STRAIN MODELING APPROACH TAKING ANTIGENIC DISTANCE INTO ACCOUNT.
Séverine Urdy
Favorite
V
Van Brantegem, Pieter

University of California, San Francisco
PI-009 - PREDICTORS AFFECTING SPUTUM CULTURE CONVERSION IN PATIENTS WITH DRUG-SUSCEPTIBLE PULMONARY TUBERCULOSIS TREATED WITH A SHORTENED DRUG REGIMEN.
Pieter Van Brantegem
Favorite
van der Heijden, Joyce

Radboud University Medical Center
PT-018 - OPTIMIZATION OF THE BETAMETHASONE DOSING REGIMEN DURING PREGNANCY: A COMBINED PLACENTA PERFUSION AND PREGNANCY PBPK MODELLING APPROACH.
Joyce van der Heijden
Favorite
van Haarst, Aernout

Celerion
LB-011 - THE EFFECT OF NASAL CONGESTION ON THE BIOAVAILABILITY OF INTRANASALLY ADMINISTERED EPINEPHRINE IN HEALTHY ADULT SUBJECTS WITH SEASONAL ALLERGIES.
Aernout van Haarst
Favorite
van Hoogdalem, Ewoud-Jan

ICON
PII-010 - THE REPLACEMENT, REDUCTION AND REFINEMENT PRINCIPLE APPLIED TO THE VINTAGE ORAL TYRAMINE CHALLENGE TEST OF MAO INHIBITORS; EVALUATION OF A REFINED AND REDUCED DESIGN WITH TYRAMINE CMAX REPLACING BLOOD PRESSURE RESPONSE.
Ewoud-Jan van Hoogdalem
Favorite
van Wijk, Rob

University of California, San Francisco
PII-019 - LINEZOLID REACHES TARGET SITE IN TUBERCULOUS MENINGITIS PATIENTS IRRESPECTIVE OF STANDARD OR HIGH RIFAMPIN DOSE.
Rob van Wijk
Favorite
Vlasakakis, Georgios

GlaxoSmithKline
PI-008 - POPULATION MODELING OF GSK3036656 PHARMACOKINETICS AND EARLY BACTERICIDAL ACTIVITY.
Georgios Vlasakakis
Favorite
Vuu, Irene

Amgen Inc.
EP-014 - ESTIMATION OF NOVEL BISPECIFIC T-CELL ENGAGER (BiTE®) MOLECULE PHARMACOKINETICS IN CYNOMOLGUS MONKEY FROM STRUCTURALLY-SIMILAR BiTE MOLECULE DATA.
Irene Vuu
Favorite
W
Wagner, Jonathan

Children's Mercy Kansas City
PII-115 - PHARMACOMETABOLOMICS OF STATIN DISPOSITION AND RESPONSE IN CHILDREN.
Jonathan Wagner
Favorite
Wang, Lei

The Ohio State University
PII-037 - MTD IN DRUG COMBO: AN EXPERT CURATED MTD DATA SET FOR EFFICIENT DRUG COMBINATION PHASE 1 TRIAL DESIGN.
Lei Wang
Favorite
Wang, Min

Mayo Clinic
PI-030 - PHARMACOGENOMICS OF DILATED CARDIOMYOPATHY: POTENTIAL ROLE OF THE CDCP1 IN CARDIAC FIBROSIS.
Min Wang
Favorite
PWIII-002 - PHARMACOGENOMICS OF DILATED CARDIOMYOPATHY: POTENTIAL ROLE OF THE CDCP1 IN CARDIAC FIBROSIS.
Min Wang
Favorite
Wang, Shuqi

Takeda Development Center Americas Inc.
PII-035 - MACHINE LEARNING-BASED DOSE OPTIMIZATION DESIGN INCORPORATING EXPOSURE-RESPONSE RELATIONSHIP IN CELL THERAPY.
Shuqi Wang
Favorite
Wang, Yehua

University of Florida
PI-001 - ASSOCIATION BETWEEN BLEEDING RISK AND INITIAL P2Y12 INHIBITOR SELECTION AND DE-ESCALATION AMONG PATIENTS WITH ACUTE CORONARY SYNDROME (ACS) AND PERCUTANEOUS CORONARY INTERVENTION (PCI).
Yehua Wang
Favorite
RWE-005 - ASSOCIATION BETWEEN BLEEDING RISK AND INITIAL P2Y12 INHIBITOR SELECTION AND DE-ESCALATION AMONG PATIENTS WITH ACUTE CORONARY SYNDROME (ACS) AND PERCUTANEOUS CORONARY INTERVENTION (PCI).
Yehua Wang
Favorite
Wang, Zhigang

Katholieke Universiteit Leuven
PII-005 - THERAPEUTIC DRUG MONITORING CAN GUIDE THE INTRAVENOUS-TO-SUBCUTANEOUS SWITCH OF INFLIXIMAB AND VEDOLIZUMAB: A PHARMACOKINETIC SIMULATION STUDY.
Zhigang Wang
Favorite
Wanounou, Maor

Hadassah-Hebrew University Medical Center
PII-048 - INTERETHNIC DIFFRENCE IN (S)-WARAIN PHARMACOKINETICS AND EXTENT OF ANTICOAGULATION BETWEEN ETHIOPIAN AND NON-ETHIOPIAN JEWS.
Maor Wanounou
Favorite
Watanabe, Akiko

Daiichi Sankyo
PII-040 - PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELLING OF VALEMETOSTAT TO INFORM DOSE RECOMMENDATIONS WHEN CO-ADMINISTERED WITH CYP3A/P-GP MODULATORS.
Akiko Watanabe
Favorite
Weber, Elijah

Gilead Sciences
PI-051 - CONCENTRATION-QTC ANALYSIS TO ASSESS THE EFFECT OF THE GS-5718 ON CARDIAC REPOLARIZATION.
Elijah Weber
Favorite
Won, Heejae

Seoul National University College of Medicine and Hospital
PII-014 - PHARMACOKINETIC DRUG INTERACTION BETWEEN FEXUPRAZAN (DWP14012), A NOVEL POTASSIUM-COMPETITIVE ACID BLOCKER, AND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS IN HEALTHY SUBJECTS.
Heejae Won
Favorite
X
Xu, Ava

University of California, San Francisco
PII-022 - RIFAPENTINE EXPOSURE-RESPONSE RELATIONSHIPS ARE DIFFERENT FOR PHASE II AND PHASE III PRIMARY EFFICACY ENDPOINTS IN TUBERCULOSIS CLINICAL TRIALS.
Ava Xu
Favorite
Xu, Christine

Sanofi
PI-068 - EXPOSURE-RESPONSE (E-R) OF DUPILUMAB IN PAEDIATRIC PATIENTS WITH MODERATE-TO-SEVERE ASTHMA.
Christine Xu
Favorite
Xu, Vivian

University at Buffalo
PT-015 - TRANSPORT AND KINASE DEPENDENT REGULATION OF TYROSINE KINASE INHIBITOR INDUCED CARDIOTOXICITY.
Vivian Xu
Favorite
Y
Yang, Jing

Pfizer
PI-018 - FIRST-IN-HUMAN (FIH) HEALTHY VOLUNTEER (HV) STUDIES FOR ONCOLOGY THERAPEUTICS: A FRAMEWORK OF APPLICATION IN EARLY ONCOLOGY CLINICAL DEVELOPMENT.
Jing Yang
Favorite
Yang, Kyunghee

DILIsym Services Division, Simulations Plus Inc.
PII-126 - QUANTITATIVE SYSTEMS TOXICOLOGY (QST) MODELING USING DILISYM INFORMED SAFE DOSE SELECTION OF EMVODODSTAT IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS.
Kyunghee Yang
Favorite
Yang, Yan-ou

Incyte Corporation
PI-037 - AN OPEN-LABEL STUDY TO ASSESS THE EFFECT OF ITRACONAZOLE AND RIFAMPIN ON INCB000928 PHARMACOKINETICS WHEN ADMINISTERED ORALLY IN HEALTHY PARTICIPANTS.
Yan-ou Yang
Favorite
Yeung, Cindy Hoi Ting

University of Waterloo
PI-076 - CANNABIDIOL EXPOSURES IN BREASTFED INFANTS COMPARED TO CHILDREN AS PREDICTED BY PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING.
Cindy Hoi Ting Yeung
Favorite
Yin, Ophelia

Agios Pharmaceuticals, Inc.
PI-056 - DOSE SELECTION FOR MITAPIVAT PEDIATRIC PHASE 3 STUDIES USING POPULATION PHARMACOKINETIC MODELING AND SIMULATION.
Ophelia Yin
Favorite
Yi, Sojeong

US Food and Drug Administration
PII-107 - A SURVEY OF REGRESSION ANALYSIS METHODS ADOPTED IN RENAL IMPAIRMENT STUDIES.
Sojeong Yi
Favorite
PWII-004 - A SURVEY OF REGRESSION ANALYSIS METHODS ADOPTED IN RENAL IMPAIRMENT STUDIES.
Sojeong Yi
Favorite
Yoon, Deok Yong

University of Florida
PII-122 - EFFECT OF THE CHOLESTYRAMINE-INDUCED ALTERATION OF BILE ACID POOL IN THE GUT ON THE PHARMACODYNAMICS OF METFORMIN: AN EXPLORATORY STUDY.
Deok Yong Yoon
Favorite
PT-002 - OPTIMIZING CLINICAL TRIALS FOR DUCHENNE MUSCULAR DYSTROPHY USING MULTIVARIATE DISEASE PROGRESSION MODELS THAT BRIDGE A FUNCTIONAL ENDPOINT AND MRI RELAXOGRAPHY OF FIVE LEG MUSCLES.
Deok Yong Yoon
Favorite
Yoon, Seonghae

Seoul National University Bundang Hospital
PI-002 - FENO AND SMOKING HISTORY, NOT EOSINOPHILIA, MAY PREDICT THE EFFICACY OF TIOTROPIUM (SPIRIVA RESPIMAT) IN UNCONTROLLED ASTHMA PATIENTS DESPITE ICS/LABA TREATMENT: A PILOT STUDY.
Seonghae Yoon
Favorite
Yue, Min

Purdue University; Eli Lilly and Company
PI-069 - EXPOSURE-RESPONSE MODELING STRATEGIES IN ONCOLOGY: IMPACT OF DOSE REDUCTIONS ON INTERPRETATION OF RESULTS.
Min Yue
Favorite
Z
Zhai, Qinglian

Leiden University Medical Center
PI-027 - EFFECT OF GENETIC VARIANTS IN TSPYL ON THE PHARMACOKINETICS OF CYCLOSPORINE.
Qinglian Zhai
Favorite
Zhang, Cindy

University of Washington
PII-078 - POPULATION PHARMACOKINETIC MODELING OF CLOFAZIMINE: CHARACTERIZING THE IMPACT OF CRYPTOSPORIDIOSIS-ASSOCIATED DIARRHEA ON ORAL DRUG PHARMACOKINETICS IN HIV-INFECTED ADULTS.
Cindy Zhang
Favorite
Zheng, Fudan

Janssen Pharmaceuticals
PI-050 - COMPARISON OF THE SYSTEMIC EXPOSURE AND PREDICTED INHIBITION OF PHARMACODYNAMIC CYTOKINE RESPONSE BY SYSTEMIC AND LOCALLY ACTING JAK INHIBITORS.
Fudan Zheng
Favorite
Zheng, Ming

Daiichi Sankyo
PI-014 - DETERMINATION OF ABSOLUTE BIOAVAILABILITY OF QUIZARTINIB USING A MICROTRACER.
Ming Zheng
Favorite
PII-039 - PHARMACOKINETICS OF INTESTINAL P-GLYCOPROTEIN SUBSTRATE DABIGATRAN ETEXILATE WITH AND WITHOUT CONCOMITANT QUIZARTINIB.
Ming Zheng
Favorite
Zheng, Zicong

University of Houston
PII-017 - REVIEW OF BISPECIFIC ANTIBODIES’ IMMUNOGENICITY IN CLINICAL DEVELOPMENT.
Zicong Zheng
Favorite
Zhou, Lian

Arcus Biosciences
PII-057 - LIMITED DRUG INTERACTION SUPPORTED BY PBPK MODELLING OF ETRUMADENANT (AB928), A NOVEL DUAL ADENOSINE RECEPTOR ANTAGONIST, UNDER COADMINISTRATION WITH A STRONG CYP3A4 AND P-GP INHIBITOR (ITRACONAZOLE) IN HEALTHY PARTICIPANTS.
Lian Zhou
Favorite
Zhou, Xujia

University of California, San Francisco
PT-014 - A GLOBAL PROTEOMICS ANALYSIS OF THE ONTOGENY OF THE BLOOD-BRAIN BARRIER.
Xujia Zhou
Favorite
Zhu, Huaqiang

GenFleet Therapeutics Inc
EP-032 - A FIRST-IN-HUMAN PHASE I STUDY OF THE GFH312 A RIPK1 INHIBITOR, EVALUATING SAFETY/TOLERABILITY AND PHARMACOKINETICS IN HEALTHY SUBJECTS.
Huaqiang Zhu
Favorite
Zhu, Min

Regeneron Pharmaceuticals, Inc.
PII-043 - TRANSLATIONAL FINDINGS FROM THE ONGOING FIRST-IN-HUMAN (FIH) STUDY OF UBAMATAMAB (REGN4018, MUC16XCD3 BISPECIFIC ANTIBODY [BSAB]) IN PATIENTS (PTS) WITH RECURRENT OVARIAN CANCER (OC): REGIMEN SELECTION.
Min Zhu
Favorite
PWII-003 - TRANSLATIONAL FINDINGS FROM THE ONGOING FIRST-IN-HUMAN (FIH) STUDY OF UBAMATAMAB (REGN4018, MUC16XCD3 BISPECIFIC ANTIBODY [BSAB]) IN PATIENTS (PTS) WITH RECURRENT OVARIAN CANCER (OC): REGIMEN SELECTION.
Min Zhu
Favorite
Zhu, Rui

Genentech
PII-085 - POPULATION-BASED EFFICACY MODELING OF OMALIZUMAB IN PEDIATRIC PATIENTS WITH MODERATE TO SEVERE PERSISTENT INADEQUATELY CONTROLLED ALLERGIC ASTHMA.
Rui Zhu
Favorite
Zhu, Xiujuan

Mayo Clinic
PII-051 - PHARMACOGENOMICS OF ACAMPROSATE AND NALTREXONE THERAPY RESPONSE IN ALCOHOL USE DISORDER (AUD)
Xiujuan Zhu
Favorite
Zou, Peng

Daiichi Sankyo Inc.
EP-033 - A PHASE 1, OPEN-LABEL, SINGLE-DOSE, NON-RANDOMIZED STUDY TO EVALUATE PHARMACOKINETICS AND PHARMACODYNAMICS OF EDOXABAN IN PEDIATRIC PATIENTS.
Peng Zou
Favorite
EP-034 - POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF EDOXABAN IN PEDIATRIC PATIENTS.
Peng Zou
Favorite